Vinayak Prasad, MD, MPH

Title(s)Professor, Epidemiology & Biostatistics
SchoolSchool of Medicine
AddressLocation Required
San Francisco CA 00001
Phone--
ORCID ORCID Icon0000-0002-6110-8221 Additional info
vCardDownload vCard

    Collapse Biography 
    Collapse Education and Training
    Michigan State UniversityBS
    University of ChicagoMD
    Johns Hopkins UniversityMPH
    University of California, San Francisco2022Diversity, Equity and Inclusion Champion Training
    Collapse Awards and Honors
    UCSF  - 2022Excellence in Teaching Award
    OHSU  - 2020Excellence in Research and Scholarship Award - Given by Internal Medicine Residency
    OHSU  - 2019J David Bristow Award - Awarded by the Graduating Medical School Class
    OHSU  - 2018Faculty Mentorship Award - Internal Medicine Residents
    Portland Business Journal  - 20175 Under 40
    OHSU  - 2017Craig Okada Teaching Award - Given by the Graduating Hematology Oncology Fellows
    Northwestern University  - 2012Gerald Grumet Award for Best Resident Teacher
    University of Chicago  - 2009Chairman's Award in Internal Medicine
    Michigan State University  - 2005Commencement Speaker College of Arts & Letters

    Collapse Overview 
    Collapse Overview
    Vinay Prasad MD MPH is Professor of Epidemiology and Biostatistics, and a practicing Hematologist Oncologist at San Francisco General Hospital and the San Francisco VA Hospital. Dr. Prasad cares for patients with a wide range of medical concerns, including classic hematology, malignant hematology, and solid tumors. He conducts research at the intersection of health policy, evidence based medicine and oncology.

    Dr. Prasad trained at the University of Chicago, Pritzker School of Medicine, where he was recipient of the Chairman's Award in Internal Medicine, given to the graduate with highest marks in Internal Medicine and its subspecialties. He finished residency in Internal Medicine at Northwestern University, where he won the Gerald Grumet Award for best resident teacher. He completed fellowship at the National Cancer Institute and National Institutes of Health in Hematology and Medical Oncology, where he was Chief Fellow, and a Cancer Prevention Fellow.

    Dr. Prasad completed his Masters in Public Health from Johns Hopkins University. For 5 years, Dr. Prasad was Assistant and then Associate Professor at the Oregon Health and Science University, where he won 4 teaching awards in consecutive years (2017-20), including the J David Bristow Award, given by the graduating medical school class to "a faculty member who exemplifies the ideals of the true physician as he or she conducts clinical practice with patients and colleagues," and the Craig Okada award for best teacher in the hematology oncology fellowship program. Dr Prasad moved to UCSF in 2020. In 2022, he won the Excellence in Teaching Award.

    Dr. Prasad studies medical evidence, clinical decision making, health policy, and cancer drug pricing. With Adam Cifu, he coined the term Medical Reversal-- a phenomenon where medical practice flip flops, and published several papers defining its scope and impact. His work on cancer drug policy has defined the appropriate role of surrogate endpoints, and probed issues of cost and value.

    He is the author of over 400 peer reviewed papers, including articles in the New England Journal of Medicine, JAMA, BMJ, Nature, the Annals of Internal Medicine and JAMA Internal Medicine. He has also written 2 peer reviewed books, published by Johns Hopkins University Press: Ending Medical Reversal and Malignant. He hosts the podcast Plenary Session, which is the #1 oncology podcast globally by downloads, and the VPZD show, a general interest science show. He is active on Youtube and Substack. On Youtube, the channel Vinay Prasad MD MPH has over 100,000 subscribers. On Substack, Dr Prasad writes Vinay Prasad's Observations and Thoughts, and co-writers Sensible Medicine.

    Dr Prasad is the author of over 100 op-eds in media outlets including the New York Times, the Washington Post, STAT, US News and World Report, and many other outlets. He has been the guest on numerous podcasts including Honestly, Breaking Points and EconTalk. He runs the research lab www.vkprasadlab.com, and has supervised over 100 trainees on research papers.

    You can learn more about his work on www.vinayakkprasad.com and https://www.youtube.com/channel/UCUibd0E2kdF9N9e-EmIbUew

    Collapse Research 
    Collapse Research Activities and Funding
    Low and No Value Care
    Arnold Ventures

    Collapse ORNG Applications 
    Collapse Featured Publications
    Collapse Collaboration Interests
    Collapse Faculty Mentoring
    Collapse Global Health

    Collapse Featured Content 
    Collapse Twitter
    Collapse Featured Videos

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. The role of surgery in metastatic cancer: the case for a pragmatic tumor-agnostic randomized trial. Future Oncol. 2023 Jan 09. Powell K, Marquart J, Olivier T, Prasad V. PMID: 36621818.
      View in: PubMed   Mentions:
    2. PAXLOVID™: A Regulatory Gamble. Am J Med. 2023 Jan 03. Miljkovic MD, Prasad V. PMID: 36608747.
      View in: PubMed   Mentions:
    3. Financial conflicts of interest of physicians followed by neurosurgical journals on Twitter. Int J Health Plann Manage. 2023 Jan 03. Powell K, McCall K, Hooda K, Prasad V, Kakkilaya A. PMID: 36597174.
      View in: PubMed   Mentions:
    4. COVID-19 vaccine induced myocarditis in young males: A systematic review. Eur J Clin Invest. 2022 Dec 28; e13947. Knudsen B, Prasad V. PMID: 36576362.
      View in: PubMed   Mentions:
    5. Sotorasib in KRASG12C mutated lung cancer: Can we rule out cracking KRAS led to worse overall survival? Transl Oncol. 2022 Dec 26; 28:101591. Olivier T, Haslam A, Prasad V. PMID: 36577165; PMCID: PMC9803768.
      View in: PubMed   Mentions:
    6. A novel trial methodology to test interventions with very large effect sizes: the case of dostarlimab in mismatch repair-deficient, locally advanced rectal cancer. Trials. 2022 Dec 24; 23(1):1044. Powell K, Olivier T, Prasad V. PMID: 36564825; PMCID: PMC9789610.
      View in: PubMed   Mentions:
    7. Time-to-event surrogate end-points in multiple myeloma randomised trials from 2005 to 2019: A surrogacy analysis. Br J Haematol. 2022 Dec 10. Etekal T, Koehn K, Sborov DW, McClune B, Prasad V, Haslam A, Berger K, Booth C, Al Hadidi S, Abdallah AO, Goodman A, Mohyuddin GR. PMID: 36495317.
      View in: PubMed   Mentions:
    8. COVID-19 vaccine boosters for young adults: a risk benefit assessment and ethical analysis of mandate policies at universities. J Med Ethics. 2022 Dec 05. Bardosh K, Krug A, Jamrozik E, Lemmens T, Keshavjee S, Prasad V, Makary MA, Baral S, Høeg TB. PMID: 36600579.
      View in: PubMed   Mentions:
    9. Association Between US Drug Price and Measures of Efficacy for Oncology Drugs Approved by the US Food and Drug Administration From 2015 to 2020. JAMA Intern Med. 2022 Dec 01; 182(12):1319-1320. Miljkovic MD, Tuia JE, Olivier T, Haslam A, Prasad V. PMID: 36315136; PMCID: PMC9623474.
      View in: PubMed   Mentions:
    10. Characteristics of measurable residual disease assessment in myeloma: a review of clinical trials from 2015-2020. Blood Cancer J. 2022 Nov 15; 12(11):155. Van Oekelen O, Birrer N, Wesson W, Galate VL, Cliff ERS, Goodman AM, Abdallah AO, Chakraborty R, Prasad V, Mohyuddin GR. PMID: 36379917; PMCID: PMC9666639.
      View in: PubMed   Mentions:
    11. Financial conflicts of interest of OncoAlert: An informal oncology professional network. J Cancer Policy. 2022 Dec; 34:100369. Powell K, Kakkilaya A, Haslam A, Prasad V. PMID: 36396090.
      View in: PubMed   Mentions:
    12. Molecular testing to deliver personalized chemotherapy recommendations: risking over and undertreatment. BMC Med. 2022 Nov 09; 20(1):392. Olivier T, Prasad V. PMID: 36348413; PMCID: PMC9644653.
      View in: PubMed   Mentions:
    13. A systematic review of basket and umbrella trials in oncology: the importance of tissue of origin and molecular target. Eur J Cancer. 2023 Jan; 178:227-233. Haslam A, Olivier T, Tuia J, Prasad V. PMID: 36493558.
      View in: PubMed   Mentions:
    14. Pembrolizumab for all. J Cancer Res Clin Oncol. 2022 Oct 22. Kim MS, Prasad V. PMID: 36271954.
      View in: PubMed   Mentions:
    15. Brentuximab Vedotin in Advanced Hodgkin's Lymphoma. N Engl J Med. 2022 10 20; 387(16):1527. Haslam A, Prasad V. PMID: 36260800.
      View in: PubMed   Mentions:
    16. What drives cancer clinical trial accrual? An empirical analysis of studies leading to FDA authorisation (2015-2020). BMJ Open. 2022 10 07; 12(10):e064458. Jenei K, Haslam A, Olivier T, Miljkovíc M, Prasad V. PMID: 36207035; PMCID: PMC9558788.
      View in: PubMed   Mentions:
    17. Estimation of time cost of anti-cancer drugs approved based on comparisons to best supportive care: A cross sectional analysis. J Cancer Policy. 2022 12; 34:100363. Prasad V, Olivier T, Chen EY, Haslam A. PMID: 36162749.
      View in: PubMed   Mentions:
    18. FDA validation of surrogate endpoints in oncology: 2005-2022. J Cancer Policy. 2022 12; 34:100364. Walia A, Haslam A, Prasad V. PMID: 36155118.
      View in: PubMed   Mentions:
    19. Relugolix: Five Reasons Why the US Food and Drug Administration Should Have Exercised Restraint. Eur Urol. 2022 Sep 21. Powell K, Burns MC, Prasad V. PMID: 36153246.
      View in: PubMed   Mentions:
    20. Lutetium-177-PSMA-617 in Metastatic Castration-resistant Prostate Cancer: Limitations of the VISION Trial. Eur Urol. 2022 Sep 09. Olivier T, Powell K, Prasad V. PMID: 36096857.
      View in: PubMed   Mentions:
    21. Crossover in Adjuvant Trastuzumab Trials: Sparing Toxicity in Patient Care. Am J Clin Oncol. 2022 Oct 01; 45(10):438-441. Tuia JE, Olivier T, Prasad VK. PMID: 36073967.
      View in: PubMed   Mentions:
    22. The AGILE trial of ivosidenib plus azacitidine versus azacitidine alone: How many limitations is too many? Transl Oncol. 2022 Nov; 25:101523. Bhatt A, Powell K, Prasad V. PMID: 36063621; PMCID: PMC9460510.
      View in: PubMed   Mentions:
    23. Control participants of randomised trials: an often forgotten, vulnerable population. Lancet Haematol. 2022 09; 9(9):e634-e636. Mohyuddin GR, Mehra N, Ryll B, Prasad V. PMID: 36055323.
      View in: PubMed   Mentions:
    24. Characteristics of Facebook's third-party medical fact checkers. Digit Health. 2022 Jan-Dec; 8:20552076221120318. Haslam A, Prasad V. PMID: 36003316; PMCID: PMC9393657.
      View in: PubMed   Mentions:
    25. Neoadjuvant checkpoint inhibition in non-small cell lung cancer: Is earlier unquestionably better than later? Transl Oncol. 2022 Oct; 24:101505. Olivier T, Prasad V. PMID: 35953223; PMCID: PMC9381437.
      View in: PubMed   Mentions:
    26. PI3K inhibitors in haematological malignancies. Lancet Oncol. 2022 08; 23(8):e362-e363. Benjamin DJ, Prasad V. PMID: 35901824.
      View in: PubMed   Mentions:    Fields:    
    27. Constructive and obsessive criticism in science. Eur J Clin Invest. 2022 Nov; 52(11):e13839. Prasad V, Ioannidis JPA. PMID: 35869811; PMCID: PMC9787955.
      View in: PubMed   Mentions:    Fields:    
    28. Common misconceptions of randomized controlled trials in oncology. Eur J Clin Invest. 2022 Nov; 52(11):e13832. Powell K, Prasad V. PMID: 35842736.
      View in: PubMed   Mentions:    Fields:    
    29. Dose modification rules and availability of growth factor support: A cross-sectional study of head-to-head cancer trials used for US FDA approval from 2009 to 2021. Eur J Cancer. 2022 09; 172:349-356. Olivier T, Haslam A, Prasad V. PMID: 35830842.
      View in: PubMed   Mentions:    Fields:    
    30. Eventual success rate and predictors of success for oncology drugs tested in phase I trials. Int J Cancer. 2023 01 15; 152(2):276-282. Haslam A, Olivier T, Powell K, Tuia J, Prasad V. PMID: 35716142.
      View in: PubMed   Mentions:    Fields:    
    31. Contact Tracing Policy for Masked Students May be an Important Confounding Variable. Pediatrics. 2022 07 01; 150(1). Høeg TB, Prasad V, Porter T. PMID: 35765968.
      View in: PubMed   Mentions:    Fields:    Translation:HumansPHPublic Health
    32. Amivantamab and Mobocertinib in Exon 20 insertions EGFR Mutant Lung Cancer, Challenge To The Current Guidelines. Transl Oncol. 2022 Jul 01; 23:101475. Olivier T, Prasad V. PMID: 35785671; PMCID: PMC9256830.
      View in: PubMed   Mentions:
    33. Ivosidenib and Azacitidine in IDH1-Mutated AML. N Engl J Med. 2022 06 30; 386(26):2536. Goodman AM, Mohyuddin GR, Prasad V. PMID: 35767449.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    34. Repositioning canakinumab for non-small cell lung cancer-important lessons for drug repurposing in oncology. Br J Cancer. 2022 09; 127(5):785-787. Lythgoe MP, Prasad V. PMID: 35739301; PMCID: PMC9427732.
      View in: PubMed   Mentions:    Fields:    
    35. Hard-wired biases in trials: maintenance azacitidine in patients with acute myeloid leukemia and framework for future trials. Blood Adv. 2022 06 14; 6(11):3329-3331. Olivier T, Prasad V, Marini BL. PMID: 35286368; PMCID: PMC9198931.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    36. Industry Relationships With Medical Oncologists: Who Are the High-Payment Physicians? JCO Oncol Pract. 2022 07; 18(7):e1164-e1169. Wright K, Meyers DE, Chisamore TM, McInnes MDF, Sismondo S, Gyawali B, Prasad V, Booth CM. PMID: 35696634.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    37. General payments from Biogen to U.S. physicians between 2015 and 2020. J Am Geriatr Soc. 2022 10; 70(10):3035-3038. Jenei K, Lythgoe MP, Prasad V. PMID: 35665914.
      View in: PubMed   Mentions:    Fields:    
    38. Cost per Event Averted in Cancer Trials in the Adjuvant Setting From 2018 to 2022. JAMA Netw Open. 2022 06 01; 5(6):e2216058. Mousavi I, Olivier T, Prasad V. PMID: 35687338; PMCID: PMC9187950.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    39. Corrigendum to 'Multi-Cancer Screening Tests: Communicating About Risks Should be Prioritized' AmJMed 2021;135(4):413-415. Am J Med. 2022 Aug; 135(8):1031. Olivier T, Gill J, Prasad V. PMID: 35624051.
      View in: PubMed   Mentions:    Fields:    
    40. Multiplicity: When many analytic plans are applied or many redundant studies are run, false-positive results are ensured. Eur J Clin Invest. 2022 08; 52(8):e13802. Powell K, Prasad V. PMID: 35488444.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    41. FDA precedents in drug approvals: Contradiction in promoting more treatment options. Eur J Cancer. 2022 07; 169:123-125. Olivier T, Prasad V. PMID: 35550951.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    42. Association of Adjuvant or Metastatic Setting With Discontinuation of Cancer Drugs in Clinical Trials. JAMA Netw Open. 2022 05 02; 5(5):e2212327. Ahmed N, Vengalasetti Y, Haslam A, Prasad V. PMID: 35576006; PMCID: PMC9112068.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    43. Accelerated approval requirements for lurbinectedin. Lancet Oncol. 2022 05; 23(5):e206. Benjamin DJ, Prasad V. PMID: 35489350.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    44. FDA decisions on new oncological drugs. Lancet Oncol. 2022 05; 23(5):585-586. Benjamin DJ, Prasad V, Lythgoe MP. PMID: 35489341.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    45. The Effect of Hospital Visitor Policies on Patients, Their Visitors, and Health Care Providers During the COVID-19 Pandemic: A Systematic Review. Am J Med. 2022 10; 135(10):1158-1167.e3. Iness AN, Abaricia JO, Sawadogo W, Iness CM, Duesberg M, Cyrus J, Prasad V. PMID: 35472383; PMCID: PMC9035621.
      View in: PubMed   Mentions:    Fields:    
    46. Chaotic advection in a recirculating flow: Effect of a fluid-flexible-solid interaction. Chaos. 2022 Apr; 32(4):043122. Prasad V, Kulkarni SS, Sharma A. PMID: 35489862.
      View in: PubMed   Mentions:    Fields:    
    47. Frequency of survival to hospital discharge after cardiopulmonary resuscitation on FOX TV's The Resident. Eur J Emerg Med. 2022 04 01; 29(2):142-143. Herrera-Perez D, Gill J, Haslam A, Crain T, Klossner Q, Prasad V. PMID: 35210379.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    48. Tebentafusp in first-line melanoma trials: An outperforming outlier. Transl Oncol. 2022 Jun; 20:101408. Olivier T, Prasad V. PMID: 35364557; PMCID: PMC8968051.
      View in: PubMed   Mentions:
    49. High US drug prices have global implications. BMJ. 2022 03 22; 376:o693. Jenei K, Prasad V, Lythgoe MP. PMID: 35318198.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    50. Targeted therapy in lung cancer: Are we closing the gap in years of life lost? Cancer Med. 2022 09; 11(18):3417-3424. Benjamin DJ, Haslam A, Gill J, Prasad V. PMID: 35315222; PMCID: PMC9487872.
      View in: PubMed   Mentions:    Fields:    
    51. Characteristics of oncology podcasts: Attitudes, speakers, conflicts. J Cancer Policy. 2022 06; 32:100329. Akman EG, Powell K, Haslam A, Prasad V. PMID: 35560266.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    52. Frontline Dual Checkpoint Inhibition in Metastatic Melanoma Over Anti-PD-1 Monotherapy: The Case for a Comparative Randomized Controlled Trial. J Clin Oncol. 2022 05 10; 40(14):1596-1597. Olivier T, Prasad V. PMID: 35258990.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    53. Cancer Drug Approvals That Displaced Existing Standard-of-Care Therapies, 2016-2021. JAMA Netw Open. 2022 03 01; 5(3):e222265. Benjamin DJ, Xu A, Lythgoe MP, Prasad V. PMID: 35289858; PMCID: PMC8924721.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    54. Post-protocol therapy and informative censoring in the CANDOR study. Lancet Oncol. 2022 03; 23(3):e97. Meirson T, Markel G, Prasad V, Goodman AM, Mohyuddin GR. PMID: 35240098.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    55. Use of Participation to Prevalence Ratio for Evaluating the Representation Status of Women in Oncology Clinical Trials-Reply. JAMA Oncol. 2022 03 01; 8(3):480. Jenei K, Meyers DE, Prasad V. PMID: 34989805.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    56. Characteristics of clinical trials for haematological malignancies from 2015 to 2020: A systematic review. Eur J Cancer. 2022 05; 167:152-160. Wesson W, Galate VL, Sborov DW, McClune B, Goodman AM, Gyawali B, Prasad V, Abbasi S, Mohyuddin GR. PMID: 35236569.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    57. Quality of biomarker defined subgroups in FDA approvals of PD-1/PD-L1 inhibitors 2014 to 2020. Int J Cancer. 2022 06 01; 150(11):1905-1910. Kim MS, Xu A, Haslam A, Prasad V. PMID: 35182072.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    58. The use and meaning of the parachute metaphor in biomedicine: a citation analysis of a systematic review and a randomized trial of the parachute for freefall. J Comp Eff Res. 2022 04; 11(6):383-390. Xu A, Prasad V. PMID: 35189694.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    59. The approval and withdrawal of melphalan flufenamide (melflufen): Implications for the state of the FDA. Transl Oncol. 2022 Apr; 18:101374. Olivier T, Prasad V. PMID: 35196605; PMCID: PMC8866737.
      View in: PubMed   Mentions: 1  
    60. Evaluating management of progressive disease for control arm patients in trials of first line PD-1 or PD-L1 inhibitor-based treatment for metastatic solid tumours. Eur J Cancer. 2022 03; 164:95-104. Maniar A, Haslam A, Prasad V. PMID: 35182927.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    61. Retrospective comparative effectiveness research: Will changing the analytical methods change the results? Int J Cancer. 2022 06 15; 150(12):1933-1940. Zaorsky NG, Wang X, Lehrer EJ, Tchelebi LT, Yeich A, Prasad VK, Chinchilli VM, Wang M. PMID: 35099077.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    62. The accelerated approval pathway in oncology: Balancing the benefits and potential harms. J Cancer Policy. 2022 06; 32:100323. Wayant C, Mohyuddin GR, Prasad V. PMID: 35560261.
      View in: PubMed   Mentions:    Fields:    
    63. Regulatory decisions diverge over aducanumab for Alzheimer's disease. BMJ. 2022 01 28; 376:e069780. Lythgoe MP, Jenei K, Prasad V. PMID: 35091420.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    64. The last word to new FDA draft guidance for cancer clinical trial eligibility criteria for patients with incurable cancer. J Cancer Policy. 2022 03; 31:100322. Lythgoe MP, Prasad V. PMID: 35559869.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    65. An estimate of rate of deviation from NCCN guideline recommendations for central nervous system imaging in trials forming basis for drug approval in first line advanced non-small cell lung cancer (NSCLC). BMC Cancer. 2022 Jan 16; 22(1):70. Sharp J, Prasad V. PMID: 35034621; PMCID: PMC8761278.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    66. Reporting of Physicians' or Investigators' Choice of Treatment in Oncology Randomized Clinical Trials. JAMA Netw Open. 2022 01 04; 5(1):e2144770. Olivier T, Haslam A, Prasad V. PMID: 35061042; PMCID: PMC8783268.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    67. How Often do Medical Specialties Question the Practices that They Perform? An Empirical, Cross-Sectional Analysis of the Published Literature. Inquiry. 2022 Jan-Dec; 59:469580211061034. Haslam A, Powell K, Prasad V. PMID: 35322719; PMCID: PMC8961376.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    68. Comparison of Classification of Indications for Allogeneic and Autologous Transplant for Adults in ASTCT Guidelines and Evidence Available in Published Literature. JAMA Intern Med. 2022 01 01; 182(1):76-78. Kim MS, Cai J, Maniar A, Kartika T, Haslam A, Prasad V. PMID: 34491275; PMCID: PMC8424524.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    69. A preliminary study of the rate of hospitals and satellite clinics worldwide for top US cancer centers. J Cancer Policy. 2022 03; 31:100319. Prasad V, Haslam A, Tuia J. PMID: 35559871.
      View in: PubMed   Mentions:    Fields:    
    70. Where are randomized trials necessary: Are smoking and parachutes good counterexamples? Eur J Clin Invest. 2022 05; 52(5):e13730. Powell K, Prasad V. PMID: 34913477.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    71. Anticancer Drugs Approved by the US Food and Drug Administration From 2009 to 2020 According to Their Mechanism of Action. JAMA Netw Open. 2021 12 01; 4(12):e2138793. Olivier T, Haslam A, Prasad V. PMID: 34905002; PMCID: PMC8672232.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    72. The FDA's latest move to expand eligibility for oncology trials - a double-edged sword? Nat Rev Clin Oncol. 2021 12; 18(12):745-746. Lythgoe MP, Prasad V. PMID: 34535789.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    73. Has the Current Oncology Value Paradigm Forgotten Patients' Time?: Too Little of a Good Thing. JAMA Oncol. 2021 12 01; 7(12):1757-1758. Fundytus A, Prasad V, Booth CM. PMID: 34436535.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    74. Artificial intelligence and magnetic resonance imaging may not make cancer screening better. J Cancer Policy. 2022 03; 31:100314. Powell K, Kim MS, Haslam A, Prasad V. PMID: 35559866.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    75. The frequency of assessment of progression in randomized oncology clinical trials. Cancer Rep (Hoboken). 2022 07; 5(7):e1527. Haslam A, Gill J, Prasad V. PMID: 34821077; PMCID: PMC9327664.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    76. Overall survival for oncology drugs approved for genomic indications. Eur J Cancer. 2022 01; 160:175-179. Haslam A, Kim MS, Prasad V. PMID: 34819251.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    77. Elacestrant in metastatic breast cancer: Is the "standard of care" meeting standard requirements? Transl Oncol. 2022 Jan; 15(1):101273. Olivier T, Prasad V. PMID: 34798371; PMCID: PMC8605291.
      View in: PubMed   Mentions:
    78. Synthetic control arms in studies of multiple myeloma and diffuse large B-cell lymphoma. Br J Haematol. 2022 03; 196(5):1274-1277. Banerjee R, Midha S, Kelkar AH, Goodman A, Prasad V, Mohyuddin GR. PMID: 34750805.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    79. The iceberg plot, improving the visualisation of therapy response in oncology in the era of sequence-directed therapy. Eur J Cancer. 2021 12; 159:56-59. Lythgoe MP, Olivier T, Prasad V. PMID: 34736043.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    80. Characteristics of Cost-effectiveness Studies for Oncology Drugs Approved in the United States From 2015-2020. JAMA Netw Open. 2021 11 01; 4(11):e2135123. Haslam A, Lythgoe MP, Greenstreet Akman E, Prasad V. PMID: 34792592; PMCID: PMC8603079.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    81. Implementation of MPOWER Package in the South-East Asia Region: Evidence from the WHO Report on the Global Tobacco Epidemic (2009-2021). Asian Pac J Cancer Prev. 2021 Nov 01; 22(S2):71-80. Kaur J, Rinkoo AV, Gouda HN, Prasad V, Pendse RN. PMID: 34780141.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansPHPublic Health
    82. Tobacco Control in the South-East Asia Region: Accelerating Impact by Building on the Achievements and Navigating the Challenges. Asian Pac J Cancer Prev. 2021 11 01; 22(S2):3-5. Prasad V, Kaur J. PMID: 34780132.
      View in: PubMed   Mentions:    Fields:    Translation:HumansPHPublic Health
    83. Cost-Effectiveness of Population Level and Individual Level Interventions to Combat Non-communicable Disease in Eastern Sub-Saharan Africa and South East Asia: A WHO-CHOICE Analysis. Int J Health Policy Manag. 2021 Nov 01; 10(11):724-733. Bertram MY, Chisholm D, Watts R, Waqanivalu T, Prasad V, Varghese C. PMID: 34273918; PMCID: PMC9278376.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    84. Tobacco Advertising, Promotion and Sponsorship in India and Indonesia: Present Regime and the Way Forward. Asian Pac J Cancer Prev. 2021 Nov 01; 22(S2):89-96. Chandra S, Rinkoo AV, Kaur J, Prasad V. PMID: 34780143.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    85. The Oncologic Drugs Advisory Committee Votes of April 2021-Implications for the Fate of Accelerated Approval. JAMA Oncol. 2021 11 01; 7(11):1607-1609. Powell K, Lythgoe MP, Prasad V. PMID: 34236432.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    86. Challenges with sex-specific subgroup analyses in oncology clinical trials for drug approvals between 2015-2020. J Cancer Policy. 2021 12; 30:100311. Jenei K, Raymakers A, Meyers DE, Prasad V. PMID: 35559802.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    87. Recommendation Reversals in Gastroenterology Clinical Practice Guidelines. J Can Assoc Gastroenterol. 2022 Apr; 5(2):98-99. Gholami R, Khan R, Ramkissoon A, Alabdulqader A, Gimpaya N, Bansal R, Scaffidi MA, Prasad V, Detsky AS, Baker JP, Grover SC. PMID: 35368318; PMCID: PMC8972276.
      View in: PubMed   Mentions:
    88. Sacituzumab govitecan in metastatic triple negative breast cancer (TNBC): Four design features in the ASCENT trial potentially favored the experimental arm. Transl Oncol. 2022 Jan; 15(1):101248. Olivier T, Prasad V. PMID: 34688044; PMCID: PMC8531666.
      View in: PubMed   Mentions: 3  
    89. An Empirical Analysis of Precision Previvorship: Are Familial and High-Risk Cancer Preventive Programs Evidence Based? Am J Med. 2022 02; 135(2):179-183. Powell K, Haslam A, Prasad V. PMID: 34678212.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    90. Multi-Cancer Screening Tests: Communicating About Risks Should be Prioritized. Am J Med. 2022 04; 135(4):413-415. Olivier T, Gill J, Prasad V. PMID: 34655543.
      View in: PubMed   Mentions:    Fields:    Translation:HumansPHPublic Health
    91. Colorectal cancer screening at a younger age: pitfalls in the model-based recommendation of the USPSTF. BMJ Evid Based Med. 2022 08; 27(4):206-208. Powell K, Prasad V. PMID: 34635479.
      View in: PubMed   Mentions:    Fields:    
    92. Trends in drug revenue among major pharmaceutical companies: A 2010-2019 cohort study. Cancer. 2022 01 15; 128(2):311-316. Meyers DE, Meyers BS, Chisamore TM, Wright K, Gyawali B, Prasad V, Sullivan R, Booth CM. PMID: 34614198.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    93. The Inclusion of Women in Global Oncology Drug Trials Over the Past 20 Years. JAMA Oncol. 2021 10 01; 7(10):1569-1570. Jenei K, Meyers DE, Prasad V. PMID: 34436541; PMCID: PMC8391769.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    94. Understanding risk of thrombosis with thrombocytopenia syndrome after Ad26.COV2.S vaccination. Front Med. 2021 12; 15(6):938-941. Kulkarni PA, Prasad V. PMID: 34595694; PMCID: PMC8482953.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCellsPHPublic Health
    95. How the US Food and Drug Administration's approval of aducanumab for Alzheimer's disease has implication for oncology and beyond. Eur J Cancer. 2021 11; 157:68-70. Lythgoe MP, Prasad V. PMID: 34487987.
      View in: PubMed   Mentions: 2     Fields:    
    96. The implications of Industry-Funded Disease Awareness Campaigns in the Rare Disease Setting. Mayo Clin Proc. 2021 09; 96(9):2305-2308. Gill J, Sarpatwari A, Prasad V. PMID: 34481596.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    97. Use of Second-line Immunotherapy in Control Arms of Randomized Clinical Trials in Kidney Cancer: A Systematic Review. JAMA Netw Open. 2021 09 01; 4(9):e2124728. Sharp J, Khaki AR, Prasad V. PMID: 34570209; PMCID: PMC8477261.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    98. An Analysis of 5 Years of Randomized Trials in Gastroenterology and Hepatology Reveals 52 Medical Reversals. Dig Dis Sci. 2022 06; 67(6):2011-2018. Yopes MC, Mozeika AM, Liebling S, Haslam A, Prasad V, Lebwohl B. PMID: 34463882.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    99. Intention to treat versus modified intention-to-treat analysis in B-cell maturation antigen and CD19 chimeric antigen receptor trials: A systematic review and meta-analysis. Eur J Cancer. 2021 10; 156:164-174. Mohyuddin GR, Atieh T, Ahmed N, Sborov D, McClune B, Abdallah AO, Goodman AM, Aziz M, Allen I, Prasad V. PMID: 34454318.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCells
    100. Idecabtagene vicleucel: questions regarding the appropriate role and cost. Br J Haematol. 2022 01; 196(2):e15-e16. Powell K, Russler-Germain D, Prasad V. PMID: 34402527.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    101. Nested and adjacent subgroups in cancer clinical trials: When the best interests of companies and patients diverge. Eur J Cancer. 2021 09; 155:163-167. Kim MS, Prasad V. PMID: 34388514.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    102. The frequency of medical reversals in a cross-sectional analysis of high-impact oncology journals, 2009-2018. BMC Cancer. 2021 Aug 03; 21(1):889. Haslam A, Gill J, Crain T, Herrera-Perez D, Chen EY, Hilal T, Kim MS, Prasad V. PMID: 34344325; PMCID: PMC8336285.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    103. After COVID-19, telemedicine may be used in addition to usual care and not in lieu of: Implications for health systems. Int J Cancer. 2021 11 01; 149(9):1723-1724. Gill J, Prasad V. PMID: 34313349; PMCID: PMC8426807.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    104. Informative censoring due to missing data in quality of life was inadequately assessed in most oncology randomized controlled trials. J Clin Epidemiol. 2021 11; 139:80-86. Olivier T, Haslam A, Prasad V. PMID: 34311054.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    105. Characteristics of Registered Studies of Chimeric Antigen Receptor Therapies: A Systematic Review. JAMA Netw Open. 2021 07 01; 4(7):e2115668. Banerjee R, Prasad V. PMID: 34236412; PMCID: PMC8267610.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    106. New drugs and options can enhance patient outcomes: But can they also erode them? Eur J Cancer. 2021 09; 154:1-3. Kim MS, Prasad V. PMID: 34217009.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    107. Reliable, cheap, fast and few: What is the best study for assessing medical practices? Randomized controlled trials or synthetic control arms? Eur J Clin Invest. 2021 Aug; 51(8):e13580. Prasad V. PMID: 33909291.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    108. The landscape of trials for smoldering multiple myeloma: endpoints, trial design, and lessons learnt. Leuk Lymphoma. 2021 11; 62(11):2793-2795. Mohyuddin GR, Ouchveridze E, Goodman A, Prasad V. PMID: 34114943.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    109. When we move cancer drugs from the second or third to the first line of treatment: what lessons can we learn from KEYNOTE-177 and JAVELIN-100. BMJ Evid Based Med. 2022 06; 27(3):151-152. Kim MS, Prasad V. PMID: 34083211.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    110. The regulatory saga of fedratinib. J Oncol Pharm Pract. 2021 Jul; 27(5):1248-1250. Khal S, Prasad V, Palumbo A. PMID: 34013823.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    111. Assessment of New Molecular Entities Approved for Cancer Treatment in 2020. JAMA Netw Open. 2021 05 03; 4(5):e2112558. Smith CEP, Prasad V. PMID: 34047795; PMCID: PMC8164099.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    112. Multiple myeloma triplet therapies: baseline characteristics and control groups. Lancet. 2021 05 01; 397(10285):1620-1621. Mohyuddin GR, Abdallah AO, McClune B, Goodman A, Prasad V. PMID: 33933200.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    113. Accurate accounting of caplacizumab cost effectiveness. Lancet Haematol. 2021 05; 8(5):e315. Goshua G, Prasad V, Lee AI, Bendapudi PK. PMID: 33894166.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    114. Evolution of the Randomized Clinical Trial in the Era of Precision Oncology. JAMA Oncol. 2021 May 01; 7(5):728-734. Del Paggio JC, Berry JS, Hopman WM, Eisenhauer EA, Prasad V, Gyawali B, Booth CM. PMID: 33764385; PMCID: PMC7995135.
      View in: PubMed   Mentions: 13     Fields:    Translation:Humans
    115. Low-Dose Computed Tomographic Screening for Lung Cancer: Time to Implement or Unresolved Questions? J Gen Intern Med. 2021 10; 36(10):3202-3204. Desai A, Prasad V. PMID: 33904047; PMCID: PMC8481428.
      View in: PubMed   Mentions:    Fields:    Translation:HumansPHPublic Health
    116. Industry payments to US physicians for cancer therapeutics: An analysis of the 2016-2018 open payments datasets. J Cancer Policy. 2021 06; 28:100283. Meyers DE, Chisamore TM, McInnes MDF, Gyawali B, Prasad V, Booth CM. PMID: 35559912.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    117. Old-fashioned Intelligence Will Always Be Needed in Medicine. Eur Urol Focus. 2021 07; 7(4):685-686. Powell K, Prasad V. PMID: 33824086.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    118. Approval and Coverage of Cancer Drugs in England, Canada, and the US. JAMA Intern Med. 2021 04 01; 181(4):509-510. Prasad V, Kim MS. PMID: 33616600.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    119. Pembrolizumab for Non-Muscle-Invasive Bladder Cancer-A Costly Therapy in Search of Evidence. JAMA Oncol. 2021 04 01; 7(4):501-502. Gill J, Prasad V. PMID: 33377964.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    120. Quality of control groups in randomised trials of multiple myeloma enrolling in the USA: a systematic review. Lancet Haematol. 2021 Apr; 8(4):e299-e304. Mohyuddin GR, Koehn K, Sborov D, McClune B, Abdallah AO, Goodman AM, Prasad V. PMID: 33770485.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    121. Reporting of Postprotocol Therapies and Attrition in Multiple Myeloma Randomized Clinical Trials: A Systematic Review. JAMA Netw Open. 2021 04 01; 4(4):e218084. Mohyuddin GR, Koehn K, Abdallah AO, Goodman AM, Prasad V. PMID: 33909053; PMCID: PMC8082314.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    122. Untangling the PROfound Trial for Advanced Prostate Cancer: Is There Really a Role for Olaparib? Eur Urol. 2021 06; 79(6):710-712. Kwon DH, Booth CM, Prasad V. PMID: 33722420.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    123. Improvement of Pediatric Liver Core Biopsy Adequacy by Reducing Laboratory-Related Tissue Fragmentation and Increasing Portal Tract Yield. Am J Clin Pathol. 2021 02 11; 155(3):461-469. Liang J, Abbuhl MF, Wang H, Prasad V, Coogan A. PMID: 32915192.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    124. Case report of a skip segment Hirschsprung's disease: A real phenomenon. Int J Surg Case Rep. 2021 Mar; 80:105630. El-Gohary Y, Skerritt C, Prasad V, Halaweish I, Wood RJ. PMID: 33592418; PMCID: PMC7893424.
      View in: PubMed   Mentions:
    125. Potential Cost Implications for All US Food and Drug Administration Oncology Drug Approvals in 2018. JAMA Intern Med. 2021 02 01; 181(2):162-167. DeMartino PC, Miljkovic MD, Prasad V. PMID: 33165499; PMCID: PMC7653539.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    126. Drug Approvals in Hepatocellular Carcinoma-Filling the Nonexistent Gap? JAMA Oncol. 2021 02 01; 7(2):173-174. Desai A, Prasad V. PMID: 33151259.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    127. Current Landscape of Immunotherapy Trials Involving the Programmed Cell Death Protein 1/Programmed Death-Ligand 1 Axis in Intrathoracic Tumors. JTO Clin Res Rep. 2021 Apr; 2(4):100149. Kareff SA, Samtani S, Burotto M, Prasad V, Kim C. PMID: 34590006; PMCID: PMC8474294.
      View in: PubMed   Mentions:
    128. Targeted Cancer Therapies. Am Fam Physician. 2021 02 01; 103(3):155-163. Smith CEP, Prasad V. PMID: 33507053.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    129. Persistent challenges with treating multiple myeloma early. Blood. 2021 01 28; 137(4):456-458. Goodman AM, Kim MS, Prasad V. PMID: 33236046.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    130. N of 1 Data Sharing: The Impact of Data Sharing within the Hematology-Oncology Drug Products Division of the US FDA. Trends Cancer. 2021 05; 7(5):395-399. Gill J, Prasad V. PMID: 33431338.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    131. Application of ASCO Value Framework to Treatment Advances in Hepatocellular Carcinoma. JCO Oncol Pract. 2021 04; 17(4):e461-e468. Chen EY, Cook M, Deig C, Arastu A, Prasad V, Nabavizadeh N, Lopez CD, Kardosh A. PMID: 33411593.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    132. Considering benefit and risk before routinely recommending SpaceOAR. Lancet Oncol. 2021 01; 22(1):11-13. Hall WA, Tree AC, Dearnaley D, Parker CC, Prasad V, Roach M, Lawton CAF. PMID: 33387489; PMCID: PMC8882263.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansPHPublic Health
    133. Pragmatic trials with prespecified subgroups: what oncologists can learn from COVID-19. Nat Rev Clin Oncol. 2021 01; 18(1):7-8. Banerjee R, Prasad V. PMID: 33139895; PMCID: PMC7604917.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCells
    134. Drug repurposing in oncology - Authors' reply. Lancet Oncol. 2020 12; 21(12):e544. Tran AA, Prasad V. PMID: 33271101.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    135. Ten years later: a review of the US 2009 institute of medicine report on conflicts of interest and solutions for further reform. BMJ Evid Based Med. 2022 02; 27(1):46-54. Torgerson T, Wayant C, Cosgrove L, Akl EA, Checketts J, Dal Re R, Gill J, Grover SC, Khan N, Khan R, Marušic A, McCoy MS, Mitchell A, Prasad V, Vassar M. PMID: 33177167.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    136. Censored patients in Kaplan-Meier plots of cancer drugs: An empirical analysis of data sharing. Eur J Cancer. 2020 12; 141:152-161. Rosen K, Prasad V, Chen EY. PMID: 33160265.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    137. Phase I trials and therapeutic intent in the age of precision oncology: What is a patient's chance of response? Eur J Cancer. 2020 11; 139:20-26. Tao DL, Kartika T, Tran A, Prasad V. PMID: 32957010.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    138. Drug repurposing for cancer treatments: a well-intentioned, but misguided strategy. Lancet Oncol. 2020 09; 21(9):1134-1136. Tran AA, Prasad V. PMID: 32888447.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    139. The response rate of alternative treatments for drugs approved on the basis of response rate. Int J Cancer. 2021 02 01; 148(3):713-722. Haslam A, Gill J, Prasad V. PMID: 32700797.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    140. The FDA approval of pembrolizumab for patients with TMB >10 mut/Mb: was it a wise decision? No. Ann Oncol. 2020 09; 31(9):1112-1114. Prasad V, Addeo A. PMID: 32771305.
      View in: PubMed   Mentions: 19     Fields:    Translation:Humans
    141. Response to Comment on "Replacing the NCCN's Blocks with Wheels: How Should Consideration of Societal Spending be Incorporated into Oncology Practice?" Pharmacoeconomics. 2020 08; 38(8):895-896. Tran A, Prasad V. PMID: 32588391.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    142. Limitations in Clinical Trials Leading to Anticancer Drug Approvals by the US Food and Drug Administration. JAMA Intern Med. 2020 08 01; 180(8):1108-1115. Hilal T, Gonzalez-Velez M, Prasad V. PMID: 32539071; PMCID: PMC7296449.
      View in: PubMed   Mentions: 15     Fields:    Translation:Humans
    143. Analysis of estimated clinical benefit of newly approved drugs for US patients with acute myeloid leukemia. Leuk Res. 2020 09; 96:106420. Tran AA, Miljkovic M, Prasad V. PMID: 32712431.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    144. US Food and Drug Administration approvals for Bruton tyrosine kinase inhibitors in patients with chronic lymphocytic leukemia: Potential inefficiencies in trial design and evidence generation. Cancer. 2020 10 01; 126(19):4270-4272. Kim MS, Prasad V. PMID: 32644193.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    145. Replacing the NCCN's Blocks with Wheels: How Should Consideration of Societal Spending be Incorporated into Oncology Practice? Pharmacoeconomics. 2020 07; 38(7):729-731. Tran AA, Prasad V. PMID: 32328981.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    146. Are Observational, Real-World Studies Suitable to Make Cancer Treatment Recommendations? JAMA Netw Open. 2020 07 01; 3(7):e2012119. Banerjee R, Prasad V. PMID: 32729916.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    147. A Timeline of Immune Checkpoint Inhibitor Approvals in Small Cell Lung Cancer. Trends Cancer. 2020 09; 6(9):736-738. Gill J, Cetnar JP, Prasad V. PMID: 32616400.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    148. The necessity of continuing to ban tobacco use in public places post-COVID-19. East Mediterr Health J. 2020 Jun 24; 26(6):630-632. El-Awa F, Fraser CP, Adib K, Hammerich A, Abdel Latif N, Fayokun R, Prasad V, Fu D, Vestal G, Schotte K, Gouda H, St Claire S. PMID: 32621493.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCellsPHPublic Health
    149. Shifting, overlapping and expanding use of "precision oncology" terminology: a retrospective literature analysis. BMJ Open. 2020 06 07; 10(6):e036357. Tran A, Klossner Q, Crain T, Prasad V. PMID: 32513891; PMCID: PMC7282391.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    150. FDA Acceptance of Surrogate End Points for Cancer Drug Approval: 1992-2019. JAMA Intern Med. 2020 06 01; 180(6):912-914. Chen EY, Haslam A, Prasad V. PMID: 32338703; PMCID: PMC7186918.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    151. Olaparib for BRCA mutant pancreas cancer: Should the POLO trial change clinical practice? Cancer. 2020 09 15; 126(18):4087-4088. Nishikawa G, Booth C, Prasad V. PMID: 32459369.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    152. Estimation of US patients with cancer who may respond to cytotoxic chemotherapy. Future Sci OA. 2020 May 25; 6(8):FSO600. Maldonado EB, Parsons S, Chen EY, Haslam A, Prasad V. PMID: 32983564; PMCID: PMC7491026.
      View in: PubMed   Mentions: 2  
    153. The Reply. Am J Med. 2020 05; 133(5):e202. Mandrola J, Cifu A, Prasad V, Foy A. PMID: 32450948.
      View in: PubMed   Mentions:    Fields:    
    154. Frequency of Medical Reversal Among Published Randomized Controlled Trials Assessing Cardiopulmonary Resuscitation (CPR). Mayo Clin Proc. 2020 05; 95(5):889-910. Herrera-Perez D, Fox-Lee R, Bien J, Prasad V. PMID: 32370852.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    155. Comparison of Industry Payments in 2017 With Annual Salary in a Cohort of Academic Oncologists. JAMA Intern Med. 2020 05 01; 180(5):797-799. Gill J, Haslam A, Crain T, Herrera-Perez D, Prasad V. PMID: 32202604; PMCID: PMC7091392.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    156. The evidence landscape in precision medicine. Sci Transl Med. 2020 04 22; 12(540). Hey SP, Gerlach CV, Dunlap G, Prasad V, Kesselheim AS. PMID: 32321867.
      View in: PubMed   Mentions: 3     Fields:    
    157. Comparison of Drugs Used for Adjuvant and Metastatic Therapy of Colon, Breast, and Non-Small Cell Lung Cancers. JAMA Netw Open. 2020 04 01; 3(4):e202488. Parsons S, Maldonado EB, Prasad V. PMID: 32275321; PMCID: PMC7148439.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    158. Relationship Between Response and Dose in Published, Contemporary Phase I Oncology Trials. J Natl Compr Canc Netw. 2020 04; 18(4):428-433. Hazim A, Mills G, Prasad V, Haslam A, Chen EY. PMID: 32259790.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    159. Acute histologic inflammatory activity and postoperative outcomes in pediatric patients with ulcerative colitis. Am J Surg. 2020 04; 219(4):592-597. Onwuka E, Huntington J, Onwuka A, Prasad V, Nwomeh B. PMID: 32209240.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCells
    160. Patient Experience Captured by Quality-of-Life Measurement in Oncology Clinical Trials. JAMA Netw Open. 2020 03 02; 3(3):e200363. Haslam A, Herrera-Perez D, Gill J, Prasad V. PMID: 32129865; PMCID: PMC7057133.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    161. Estimation of the Percentage of US Patients With Cancer Who Are Eligible for Immune Checkpoint Inhibitor Drugs. JAMA Netw Open. 2020 03 02; 3(3):e200423. Haslam A, Gill J, Prasad V. PMID: 32150268; PMCID: PMC7063495.
      View in: PubMed   Mentions: 31     Fields:    Translation:Humans
    162. News Coverage of the American Cancer Society's Update to Colorectal Cancer Screening Guidelines. Mayo Clin Proc. 2020 03; 95(3):617-618. Krigel A, Prasad VK, Lebwohl B. PMID: 32138893.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansPHPublic Health
    163. Statistical significance and clinical evidence - Authors' reply. Lancet Oncol. 2020 03; 21(3):e119. Prasad V, Booth CM. PMID: 32135103.
      View in: PubMed   Mentions:    Fields:    
    164. Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-Mutated Colorectal Cancer. N Engl J Med. 2020 02 27; 382(9):876. Prasad V. PMID: 32101676.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    165. Medical Reversals in Family Practice: A Review. Curr Ther Res Clin Exp. 2020; 92:100579. Haslam A, Livingston C, Prasad V. PMID: 32180846; PMCID: PMC7063107.
      View in: PubMed   Mentions: 1     Fields:    
    166. Oncology Drug Advisory Committee Recommendations and the US Food and Drug Administration's Actions. Mayo Clin Proc. 2020 02; 95(2):424-426. Haslam A, Gill J, Prasad V. PMID: 32029095.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    167. An Empirical Analysis of Noninferiority Studies in Oncology: Are They Good Enough? J Natl Compr Canc Netw. 2020 02; 18(2):161-167. Haslam A, Gill J, Prasad V. PMID: 32023529.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    168. Characteristics of Public Comments Submitted to State Health Technology Assessment Programs in Oregon and Washington. JAMA Intern Med. 2020 02 01; 180(2):329-331. Ahn R, Herrera-Perez D, Prasad V. PMID: 31710334; PMCID: PMC6865292.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    169. The Clinical Trials Portfolio for On-label and Off-label Studies of Eculizumab. JAMA Intern Med. 2020 02 01; 180(2):315-317. Kim MS, Prasad V. PMID: 31657842; PMCID: PMC6820044.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    170. Comparison of three multi-cryoprotectant loading protocols for vitrification of porcine articular cartilage. Cryobiology. 2020 02 01; 92:151-160. Wu K, Shardt N, Laouar L, Chen Z, Prasad V, Elliott JAW, Jomha NM. PMID: 31917159.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansAnimalsCells
    171. Our best weapons against cancer are not magic bullets. Nature. 2020 01; 577(7791):451. Prasad V. PMID: 31965108.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    172. Concerning survival signal for eltrombopag in MDS/AML. Leuk Lymphoma. 2020 04; 61(4):1002-1003. Tao D, Prasad V. PMID: 31786967.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    173. Multiplicity and the marginal benefits of bevacizumab in malignant solid tumours. Curr Oncol. 2019 12; 26(6):e791-e792. Gay ND, Tao D, Prasad V. PMID: 31896950; PMCID: PMC6927779.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    174. Clinical Risk During the Evaluation of Genomic Risk for Hormone-Sensitive Breast Cancer: Ignoring Valuable Data. J Natl Compr Canc Netw. 2019 12; 17(12):1456-1458. Khaki AR, Gadi VK, Prasad V. PMID: 31805524.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    175. Multiplicity in oncology randomised controlled trials: a threat to medical evidence? Lancet Oncol. 2019 12; 20(12):1638-1640. Prasad V, Booth CM. PMID: 31797779.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    176. Examining the Use of Real-World Evidence in the Regulatory Process. Clin Pharmacol Ther. 2020 04; 107(4):843-852. Beaulieu-Jones BK, Finlayson SG, Yuan W, Altman RB, Kohane IS, Prasad V, Yu KH. PMID: 31562770; PMCID: PMC7093234.
      View in: PubMed   Mentions: 16     Fields:    Translation:Humans
    177. Medical reversals in low- and middle-income countries. Int J Health Plann Manage. 2020 Mar; 35(2):631-638. Haslam A, Prasad V, Livingston C. PMID: 31710144.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    178. Estimation of Percentage of Patients With Fibroblast Growth Factor Receptor Alterations Eligible for Off-label Use of Erdafitinib. JAMA Netw Open. 2019 11 01; 2(11):e1916091. de Almeida Carvalho LM, de Oliveira Sapori Avelar S, Haslam A, Gill J, Prasad V. PMID: 31755953; PMCID: PMC6902826.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    179. A method to determine if more than surrogate outcomes were improved: The EMR glitch experiment. Res Pract Thromb Haemost. 2020 Jan; 4(1):19-22. Gill J, Prasad V. PMID: 31989081; PMCID: PMC6971317.
      View in: PubMed   Mentions:
    180. Use of targeted therapies for advanced renal cell carcinoma in the Veterans Health Administration. Cancer Med. 2019 11; 8(15):6651-6661. Aspinall SL, Zhao X, Geraci MC, Good CB, Cunningham FE, Heron BB, Becker D, Lee S, Prasad V, Targeted Therapies in Veterans with RCC Study Group. PMID: 31536684; PMCID: PMC6825975.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    181. The Reply. Am J Med. 2019 09; 132(9):e719. Mandrola J, Cifu A, Prasad V, Foy A. PMID: 31606062.
      View in: PubMed   Mentions:    Fields:    
    182. A systematic review of head-to-head trials of approved monoclonal antibodies used in cancer: an overview of the clinical trials agenda. J Cancer Res Clin Oncol. 2019 Sep; 145(9):2303-2311. Luo J, Nishikawa G, Prasad V. PMID: 31396700.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    183. A reality check of the accelerated approval of immune-checkpoint inhibitors. Nat Rev Clin Oncol. 2019 11; 16(11):656-658. Gill J, Prasad V. PMID: 31383994.
      View in: PubMed   Mentions: 14     Fields:    Translation:Humans
    184. An Overview of Cancer Drugs Approved by the US Food and Drug Administration Based on the Surrogate End Point of Response Rate. JAMA Intern Med. 2019 07 01; 179(7):915-921. Chen EY, Raghunathan V, Prasad V. PMID: 31135822; PMCID: PMC6547222.
      View in: PubMed   Mentions: 29     Fields:    Translation:Humans
    185. A comprehensive review of randomized clinical trials in three medical journals reveals 396 medical reversals. Elife. 2019 06 11; 8. Herrera-Perez D, Haslam A, Crain T, Gill J, Livingston C, Kaestner V, Hayes M, Morgan D, Cifu AS, Prasad V. PMID: 31182188; PMCID: PMC6559784.
      View in: PubMed   Mentions: 24     Fields:    Translation:Humans
    186. Interpreting the Effectiveness of Cancer Screening From National Population Statistics: Is It Sound Practice? Mayo Clin Proc. 2019 06; 94(6):951-956. Chapa J, Haslam A, Prasad V. PMID: 31171133.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansPHPublic Health
    187. Real-world Evidence-What Does It Really Mean? JAMA Oncol. 2019 Jun 01; 5(6):781-783. Nabhan C, Klink A, Prasad V. PMID: 31095259.
      View in: PubMed   Mentions: 15     Fields:    Translation:Humans
    188. Analysis of Control Arm Quality in Randomized Clinical Trials Leading to Anticancer Drug Approval by the US Food and Drug Administration. JAMA Oncol. 2019 Jun 01; 5(6):887-892. Hilal T, Sonbol MB, Prasad V. PMID: 31046071; PMCID: PMC6499129.
      View in: PubMed   Mentions: 15     Fields:    Translation:Humans
    189. Registration studies - when should patients be deemed ineligible for aggressive therapy? Nat Rev Clin Oncol. 2019 06; 16(6):333-334. Cook RJ, Gill J, Prasad V. PMID: 30778146.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    190. Confirmatory Trials for Drugs Approved on a Single Trial. Circ Cardiovasc Qual Outcomes. 2019 06; 12(6):e005494. Haslam A, Prasad V. PMID: 31137954.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    191. Should Evidence Come with an Expiration Date? J Gen Intern Med. 2019 07; 34(7):1356-1357. Greene P, Prasad V, Cifu A. PMID: 31062228; PMCID: PMC6614217.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansPHPublic Health
    192. Reply to C.J. Sweeney et al. J Clin Oncol. 2019 07 01; 37(19):1680-1681. Parikh RB, Prasad V. PMID: 31050910; PMCID: PMC6879314.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    193. Estimation of the Percentage of US Patients With Cancer Who Are Eligible for and Respond to Checkpoint Inhibitor Immunotherapy Drugs. JAMA Netw Open. 2019 05 03; 2(5):e192535. Haslam A, Prasad V. PMID: 31050774; PMCID: PMC6503493.
      View in: PubMed   Mentions: 265     Fields:    Translation:Humans
    194. Assessment of Accuracy of Waterfall Plot Representations of Response Rates in Cancer Treatment Published in Medical Journals. JAMA Netw Open. 2019 05 03; 2(5):e193981. Kim MS, Prasad V. PMID: 31099871; PMCID: PMC6537809.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    195. Estimation of Study Time Reduction Using Surrogate End Points Rather Than Overall Survival in Oncology Clinical Trials. JAMA Intern Med. 2019 05 01; 179(5):642-647. Chen EY, Joshi SK, Tran A, Prasad V. PMID: 30933235; PMCID: PMC6503556.
      View in: PubMed   Mentions: 19     Fields:    Translation:Humans
    196. Case Reports in the Age of Twitter. Am J Med. 2019 10; 132(10):e725-e726. Cifu AS, Vandross AL, Prasad V. PMID: 30998916.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    197. Testing Healthcare Workers for Latent Tuberculosis: Is It Evidence Based, Bio-Plausible, Both, Or Neither? Am J Med. 2019 11; 132(11):1260-1261. Gill J, Prasad V. PMID: 30946831.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansPHPublic Health
    198. Recenti Prog Med. 2019 04; 110(4):156-158. Mandrola J, Cifu A, Prasad V, Foy A. PMID: 31066360.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    199. Testing for blinding in sham-controlled studies for procedural interventions: the third-party video method. CMAJ. 2019 03 11; 191(10):E272-E273. Gill J, Prasad V. PMID: 30858182; PMCID: PMC6411475.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    200. The Case for Being a Medical Conservative. Am J Med. 2019 08; 132(8):900-901. Mandrola J, Cifu A, Prasad V, Foy A. PMID: 30851263.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    201. Cancer screening: A modest proposal for prevention. Cleve Clin J Med. 2019 03; 86(3):157-160. Kim MS, Nishikawa G, Prasad V. PMID: 30849032.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    202. Improving the design of pivotal clinical trials. Clin Adv Hematol Oncol. 2019 Mar; 17(3):150-152. Prasad VK. PMID: 30969951.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    203. Where Does the Blame for High Health Care Costs Go? An Empirical Analysis of Newspaper and Journal Articles Criticizing Health Care Costs. Am J Med. 2019 06; 132(6):718-721. Haslam A, Crain T, Gill J, Herrera-Perez D, Prasad V. PMID: 30639552.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    204. Metastasis-Free Survival in Prostate Cancer: Faster Drug Approvals, Better Drugs? J Clin Oncol. 2019 02 01; 37(4):266-268. Parikh RB, Prasad V. PMID: 30532985.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    205. A systematic review of trial-level meta-analyses measuring the strength of association between surrogate end-points and overall survival in oncology. Eur J Cancer. 2019 01; 106:196-211. Haslam A, Hey SP, Gill J, Prasad V. PMID: 30528804.
      View in: PubMed   Mentions: 34     Fields:    Translation:Humans
    206. Addendum: Low-value approvals and high prices might incentivize ineffective drug development. Nat Rev Clin Oncol. 2018 12; 15(12):787. Prasad V, McCabe C, Mailankody S. PMID: 30420734.
      View in: PubMed   Mentions:    Fields:    
    207. Moving Precision Oncology Forward Amid Myths and Misconceptions-Reply. JAMA Oncol. 2018 12 01; 4(12):1790. Marquart J, Chen EY, Prasad V. PMID: 30419080.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    208. Accounting for All Costs in the Total Cost of Chimeric Antigen Receptor T-Cell Immunotherapy-Reply. JAMA Oncol. 2018 12 01; 4(12):1785-1786. Hernandez I, Prasad V, Gellad WF. PMID: 30325998.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCells
    209. Correction to: Do Limitations in the Design of PARADIGM-HF Justify the Slow Real World Uptake of Sacubitril/Valsartan (Entresto)? Cardiovasc Drugs Ther. 2018 12; 32(6):637. Ahn R, Prasad V. PMID: 30276760.
      View in: PubMed   Mentions:    Fields:    
    210. Do Limitations in the Design of PARADIGM-HF Justify the Slow Real World Uptake of Sacubitril/Valsartan (Entresto)? Cardiovasc Drugs Ther. 2018 12; 32(6):633-635. Ahn R, Prasad V. PMID: 30232657.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    211. Eliminating MRD - FDA approval of blinatumomab for B-ALL in complete remission. Nat Rev Clin Oncol. 2018 12; 15(12):727-728. Hilal T, Prasad V. PMID: 30181661.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    212. Brentuximab vedotin for frontline Hodgkin lymphoma: How much will a successful trial cost patients and payers? Eur J Cancer. 2018 11; 104:252-253. Shanbhag S, Prasad V. PMID: 30342911.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    213. Inconsistent Reporting of Potential Conflicts of Interest. JAMA Oncol. 2018 10 01; 4(10):1439. Prasad V. PMID: 30128488.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    214. Inconsistent Reporting of Potential Conflicts of Interest. JAMA Intern Med. 2018 10 01; 178(10):1424-1425. Prasad V. PMID: 30105361.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    215. Meaningful and Accurate Disclosure of Conflict of Interest at the ASTRO National Meeting: A Need for Reassessment of Current Policies. J Oncol Pract. 2018 Sep 27; JOP1800121. Ahmed AA, Yoo SK, Mehta S, Holliday EB, Deville C, Vapiwala N, Wilson LD, Jagsi R, Prasad V, Thomas CR. PMID: 30260714.
      View in: PubMed   Mentions: 1     Fields:    
    216. Diagnostic expansion in clinical trials: myocardial infarction, stroke, cancer recurrence, and metastases may not be the hard endpoints you thought they were. BMJ. 2018 Sep 19; 362:k3783. Nishikawa G, Prasad V. PMID: 30232089.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    217. The Tradeoff of Cancer Drug Regulatory Policy: Faster Approvals for One Means Less Knowledge for Another. Am J Med. 2019 03; 132(3):e509-e511. Tao D, Schott S, Prasad V. PMID: 30201241.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    218. Choice of control group in randomised trials of cancer medicine: are we testing trivialities? Lancet Oncol. 2018 09; 19(9):1150-1152. Tao D, Prasad V. PMID: 30191836.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    219. Improving observational studies in the era of big data. Lancet. 2018 09 01; 392(10149):716-717. Gill J, Prasad V. PMID: 30191816.
      View in: PubMed   Mentions: 7     Fields:    
    220. Inconsistent Reporting of Potential Conflicts of Interest. JAMA Pediatr. 2018 09 01; 172(9):886. Prasad V. PMID: 30073291.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    221. Clarification of the FDA Accelerated Agnostic Approval of Pembrolizumab and the Opportunities Arising From the Required Confirmatory Studies-Reply. JAMA Oncol. 2018 09 01; 4(9):1300-1301. Prasad V, Kaestner V, Mailankody S. PMID: 29978197.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCells
    222. A pooled analysis of published, basket trials in cancer medicine. Eur J Cancer. 2018 09; 101:244-250. Hazim A, Prasad V. PMID: 30096705.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    223. Estimation of the Percentage of US Patients With Cancer Who Benefit From Genome-Driven Oncology. JAMA Oncol. 2018 08 01; 4(8):1093-1098. Marquart J, Chen EY, Prasad V. PMID: 29710180; PMCID: PMC6143048.
      View in: PubMed   Mentions: 86     Fields:    Translation:Humans
    224. The Necessity of Sham Controls. Am J Med. 2019 02; 132(2):e29-e30. Prasad V, Cifu AS. PMID: 30076810.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    225. A comprehensive review of exceptional responders to anticancer drugs in the biomedical literature. Eur J Cancer. 2018 09; 101:143-151. Nishikawa G, Luo J, Prasad V. PMID: 30059818.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    226. Inconsistent Reporting of Potential Conflicts of Interest. JAMA. 2018 07 24; 320(4):408. Prasad V. PMID: 30043054.
      View in: PubMed   Mentions:    Fields:    
    227. Multivitamins Do Not Reduce Cardiovascular Disease and Mortality and Should Not Be Taken for This Purpose: How Do We Know That? Circ Cardiovasc Qual Outcomes. 2018 07; 11(7):e004886. Haslam A, Prasad V. PMID: 29991647.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    228. Cost-effectiveness of Nusinersen for Spinal Muscular Atrophy-Reply. JAMA Pediatr. 2018 07 01; 172(7):701-702. Prasad V. PMID: 29800980.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    229. Low-value approvals and high prices might incentivize ineffective drug development. Nat Rev Clin Oncol. 2018 07; 15(7):399-400. Prasad V, McCabe C, Mailankody S. PMID: 29760505.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    230. PFO closure for secondary stroke prevention: is the discussion closed? J Thromb Thrombolysis. 2018 Jul; 46(1):74-76. Shatzel JJ, Daughety MM, Prasad V, DeLoughery TG. PMID: 29464458.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansPHPublic Health
    231. Total Costs of Chimeric Antigen Receptor T-Cell Immunotherapy. JAMA Oncol. 2018 07 01; 4(7):994-996. Hernandez I, Prasad V, Gellad WF. PMID: 29710129; PMCID: PMC6145722.
      View in: PubMed   Mentions: 21     Fields:    Translation:Humans
    232. Direct-to-Consumer Genetic Testing: The Implications of the US FDA's First Marketing Authorization for BRCA Mutation Testing. JAMA. 2018 Jun 19; 319(23):2377-2378. Gill J, Obley AJ, Prasad V. PMID: 29800087.
      View in: PubMed   Mentions: 17     Fields:    Translation:Humans
    233. The need to assess financial adverse events. Lancet Haematol. 2018 Nov; 5(11):e508-e509. Nastoupil LJ, Prasad V, Flowers CR. PMID: 29907551.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    234. If the IMPROVE-IT Trial Was Positive, as Reported, Why Did the FDA Denied Expanded Approval for Ezetimibe and Simvastatin? An Explanation of the Tipping Point Analysis. J Gen Intern Med. 2018 08; 33(8):1213-1214. Deloughery EP, Prasad V. PMID: 29869138; PMCID: PMC6082210.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    235. Concerns About the Approval of Nusinersen Sodium by the US Food and Drug Administration. JAMA Intern Med. 2018 06 01; 178(6):743-744. Gerrity MS, Prasad V, Obley AJ. PMID: 29710299.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    236. Assessing Pharmaceutical Research and Development Costs-Reply. JAMA Intern Med. 2018 04 01; 178(4):588-589. Prasad V, Mailankody S. PMID: 29610885.
      View in: PubMed   Mentions: 2     Fields:    
    237. Overall Survival vs Disease-Specific Survival-Reply. JAMA Oncol. 2018 04 01; 4(4):586-587. Mailankody S, Prasad V. PMID: 29167883.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    238. Frequency and level of evidence used in recommendations by the National Comprehensive Cancer Network guidelines beyond approvals of the US Food and Drug Administration: retrospective observational study. BMJ. 2018 03 07; 360:k668. Wagner J, Marquart J, Ruby J, Lammers A, Mailankody S, Kaestner V, Prasad V. PMID: 29514787; PMCID: PMC5838851.
      View in: PubMed   Mentions: 14     Fields:    Translation:Humans
    239. Financial Conflicts of Interest at FDA Drug Advisory Committee Meetings. Hastings Cent Rep. 2018 Mar; 48(2):10-13. Hayes MJ, Prasad V. PMID: 29590518.
      View in: PubMed   Mentions: 9     Fields:    
    240. Cancer Drugs Approved Based on Biomarkers and Not Tumor Type-FDA Approval of Pembrolizumab for Mismatch Repair-Deficient Solid Cancers. JAMA Oncol. 2018 Feb 01; 4(2):157-158. Prasad V, Kaestner V, Mailankody S. PMID: 29285544.
      View in: PubMed   Mentions: 52     Fields:    Translation:HumansCells
    241. Nusinersen for Spinal Muscular Atrophy: Are We Paying Too Much for Too Little? JAMA Pediatr. 2018 02 01; 172(2):123-125. Prasad V. PMID: 29228077.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    242. The relation between publication rate and financial conflict of interest among physician authors of high-impact oncology publications: an observational study. CMAJ Open. 2018 Jan 30; 6(1):E57-E62. Kaestner V, Edmiston JB, Prasad V. PMID: 29382668; PMCID: PMC5878961.
      View in: PubMed   Mentions: 1     Fields:    
    243. Most medical practices are not parachutes: a citation analysis of practices felt by biomedical authors to be analogous to parachutes. CMAJ Open. 2018 Jan 15; 6(1):E31-E38. Hayes MJ, Kaestner V, Mailankody S, Prasad V. PMID: 29343497; PMCID: PMC5878948.
      View in: PubMed   Mentions: 7     Fields:    
    244. Pemetrexed in Nonsquamous Non-Small-Cell Lung Cancer: The Billion Dollar Subgroup Analysis. JAMA Oncol. 2018 Jan 01; 4(1):17-18. Gyawali B, Prasad V. PMID: 28750129.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    245. Non-Inferiority Trials in Medicine: Practice Changing or a Self-Fulfilling Prophecy? J Gen Intern Med. 2018 01; 33(1):3-5. Prasad V. PMID: 28980180; PMCID: PMC5756169.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    246. Is "Precision Medicine" Ready to Use in Primary Care Practice? No: It Is Barely Ready for Testing. Am Fam Physician. 2017 Dec 15; 96(12):769-770. Prasad V, Obley A. PMID: 29431373.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    247. Clinically meaningful benefit: real world use compared against the American and European guidelines. Blood Cancer J. 2017 12 14; 7(12):645. Dreicer JJ, Mailankody S, Fakhrejahani F, Prasad V. PMID: 29238046; PMCID: PMC5802502.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    248. Overestimating the Benefit of Cancer Drugs. JAMA Oncol. 2017 12 01; 3(12):1737-1738. Prasad V. PMID: 28715568.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    249. Time from US Food and Drug Administration approval to publication of data for cancer drugs: a comparison of first and subsequent approvals. Blood Cancer J. 2017 11 30; 7(12):637. Lammers A, Wang R, Cetnar J, Prasad V. PMID: 29187747; PMCID: PMC5802585.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    250. Me too-drugs with limited benefits - the tale of regorafenib for HCC. Nat Rev Clin Oncol. 2018 01; 15(1):62. Gyawali B, Prasad V. PMID: 29182165.
      View in: PubMed   Mentions: 4     Fields:    
    251. Is "Do Everything!" Always Appropriate?-Reply. JAMA Oncol. 2017 11 01; 3(11):1588. Beer TM, Prasad V. PMID: 28817761.
      View in: PubMed   Mentions: 1     Fields:    
    252. Research and Development Spending to Bring a Single Cancer Drug to Market and Revenues After Approval. JAMA Intern Med. 2017 11 01; 177(11):1569-1575. Prasad V, Mailankody S. PMID: 28892524; PMCID: PMC5710275.
      View in: PubMed   Mentions: 86     Fields:    Translation:Humans
    253. Do cancer drugs improve survival or quality of life? BMJ. 2017 10 04; 359:j4528. Prasad V. PMID: 28978548; PMCID: PMC5695531.
      View in: PubMed   Mentions: 18     Fields:    Translation:Humans
    254. Immunotherapy: Tisagenlecleucel - the first approved CAR-T-cell therapy: implications for payers and policy makers. Nat Rev Clin Oncol. 2018 01; 15(1):11-12. Prasad V. PMID: 28975930.
      View in: PubMed   Mentions: 67     Fields:    Translation:Humans
    255. Conflicts of interest in Twitter. Lancet Haematol. 2017 09; 4(9):e408-e409. Kaestner V, Brown A, Tao D, Prasad V. PMID: 28863800.
      View in: PubMed   Mentions: 6     Fields:    
    256. Evolocumab in Patients with Cardiovascular Disease. N Engl J Med. 2017 08 24; 377(8):786-7. Redberg RF, Prasad V. PMID: 28836420.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    257. A further strategy to combat the high price of anticancer drugs. Nat Rev Clin Oncol. 2017 10; 14(10):629. Prasad V, De Jesús K, Mailankody S. PMID: 28829055.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    258. Surrogate endpoints in oncology: when are they acceptable for regulatory and clinical decisions, and are they currently overused? BMC Med. 2017 07 21; 15(1):134. Kemp R, Prasad V. PMID: 28728605; PMCID: PMC5520356.
      View in: PubMed   Mentions: 48     Fields:    Translation:Humans
    259. Health policy: Me-too drugs with limited benefits - the tale of regorafenib for HCC. Nat Rev Clin Oncol. 2017 11; 14(11):653-654. Gyawali B, Prasad V. PMID: 28719584.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    260. Nivolumab and pembrolizumab: Monoclonal antibodies against programmed cell death-1 (PD-1) that are interchangeable. Semin Oncol. 2017 04; 44(2):132-135. Prasad V, Kaestner V. PMID: 28923211.
      View in: PubMed   Mentions: 37     Fields:    Translation:Humans
    261. Financial Conflict of Interest and Academic Influence Among Experts Speaking on Behalf of the Pharmaceutical Industry at the US Food and Drug Administration's Oncologic Drugs Advisory Committee Meetings. Mayo Clin Proc. 2017 07; 92(7):1164-1166. Lammers A, Edmiston J, Kaestner V, Prasad V. PMID: 28688469.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    262. Limitations Concerning the Association of Physician Sex and Patient Outcomes. JAMA Intern Med. 2017 07 01; 177(7):1058. Friedberg MW, Gellad WF, Prasad V. PMID: 28672361.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    263. Overall Survival in Cancer Drug Trials as a New Surrogate End Point for Overall Survival in the Real World. JAMA Oncol. 2017 07 01; 3(7):889-890. Mailankody S, Prasad V. PMID: 27892992.
      View in: PubMed   Mentions: 13     Fields:    Translation:Humans
    264. Pembrolizumab as first-line therapy in programmed death ligand 1-positive advanced lung cancer: Is it as effective as we think it is? Cancer. 2017 10 15; 123(20):3872-3874. Goldstein DA, Bilal U, Prasad V. PMID: 28662268.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    265. Pharmaceutical Marketing for Rare Diseases: Regulating Drug Company Promotion in an Era of Unprecedented Advertisement. JAMA. 2017 06 27; 317(24):2479-2480. Mailankody S, Prasad V. PMID: 28520871.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    266. Combining drugs and extending treatment - a PFS end point is not sufficient. Nat Rev Clin Oncol. 2017 09; 14(9):521-522. Gyawali B, Prasad V. PMID: 28534528.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    267. Extrarenal Wilms Tumor With Skeletal and Glial Differentiation. Int J Surg Pathol. 2018 Feb; 26(1):34. Tan GC, Prasad V. PMID: 28508688.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    268. Closed Financial Loops: When They Happen in Government, They're Called Corruption; in Medicine, They're Just a Footnote. Hastings Cent Rep. 2017 May; 47(3):9-14. De Jesus-Morales K, Prasad V. PMID: 28543414.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    269. Curbing tobacco's reach to improve people's health and futures. Int J Tuberc Lung Dis. 2017 05 01; 21(5):481-482. Prasad V, Fu D. PMID: 28399959.
      View in: PubMed   Mentions:    Fields:    Translation:HumansAnimals
    270. Heparin-induced thrombocytopenia: a tremendous opportunity for randomization. Blood Coagul Fibrinolysis. 2017 Apr; 28(3):272-274. Lammers A, DeLoughery T, Prasad V. PMID: 27787285.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    271. How the USPSTF's Mammographic Screening Guidelines Should Be Interpreted. Am J Med. 2017 Jul; 130(7):769-770. Prasad V. PMID: 28344145.
      View in: PubMed   Mentions:    Fields:    Translation:HumansPHPublic Health
    272. The high price of anticancer drugs: origins, implications, barriers, solutions. Nat Rev Clin Oncol. 2017 Jun; 14(6):381-390. Prasad V, De Jesús K, Mailankody S. PMID: 28290490.
      View in: PubMed   Mentions: 93     Fields:    Translation:Humans
    273. Drugs that lack single-agent activity: are they worth pursuing in combination? Nat Rev Clin Oncol. 2017 04; 14(4):193-194. Gyawali B, Prasad V. PMID: 28266519.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    274. Financial Conflicts of Interest Among Hematologist-Oncologists on Twitter. JAMA Intern Med. 2017 03 01; 177(3):425-427. Tao DL, Boothby A, McLouth J, Prasad V. PMID: 28114456.
      View in: PubMed   Mentions: 14     Fields:    Translation:Humans
    275. What constitutes an "unmet medical need" in oncology? An empirical evaluation of author usage in the biomedical literature. Semin Oncol. 2017 02; 44(1):8-12. Lu E, Shatzel J, Shin F, Prasad V. PMID: 28395768.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    276. The Rising Price of Cancer Drugs-A New Old Problem? JAMA Oncol. 2017 Feb 01; 3(2):277-278. Prasad V, Wang R, Afifi SH, Mailankody S. PMID: 27711927.
      View in: PubMed   Mentions: 7     Fields:    
    277. Pediatric Xanthogranulomatous Cystitis: The First Described Case in a Pre-pubertal Male and Review of the Literature. Pediatr Dev Pathol. 2017 Jul-Aug; 20(4):330-334. Preece J, Prasad V, McLeod D. PMID: 28727973.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    278. Taking Care of Our Friends and Neighbors: DeVita's The Death of Cancer and the Challenge of Letting Go. JAMA Oncol. 2017 Jan 01; 3(1):16-17. Beer TM, Prasad V. PMID: 27631115.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    279. A Retrospective Cohort Study of Total Colonic Aganglionosis: Is the Appendix a Reliable Diagnostic Tool? J Neonatal Surg. 2017 Jan-Mar; 6(1):25. Reck-Burneo CA, Lane V, Vinay P, Wood R, Levitt M. PMID: 28083511; PMCID: PMC5224759.
      View in: PubMed   Mentions:
    280. Effect of the American Society of Clinical Oncology's Conflict of Interest Policy on Information Overload. JAMA Oncol. 2016 Dec 01; 2(12):1653-1654. Boothby A, Wang R, Cetnar J, Prasad V. PMID: 27560393.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    281. Industry Funding of Cancer Patient Advocacy Organizations. Mayo Clin Proc. 2016 11; 91(11):1668-1670. Abola MV, Prasad V. PMID: 27814841.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    282. Same Data; Different Interpretations. J Clin Oncol. 2016 11 01; 34(31):3729-3732. Gyawali B, Prasad V. PMID: 27573659; PMCID: PMC5477922.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    283. Pediatric Dermatology Photoquiz: An Enlarging Facial Papule. Pediatr Dermatol. 2016 Nov; 33(6):661-662. Yanes DA, Prasad V, Fernandez Faith E. PMID: 27882660.
      View in: PubMed   Mentions:    Fields:    
    284. A Strategy for Helicobacter Immunohistochemistry Utilization in Pediatric Practice:  Insights From Morphologic and Cost-Benefit Analyses. Am J Clin Pathol. 2016 Nov 01; 146(5):611-617. Conces MR, Arnold CA, Baker PB, Carter CM, Fung B, Prasad V, Arnold MA. PMID: 28430952.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCells
    285. Precision medicine in diffuse large B-cell lymphoma: Hype or hope? Eur J Cancer. 2016 11; 68:22-26. Prasad V. PMID: 27697586.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    286. Future jobs of FDA's haematology-oncology reviewers. BMJ. 2016 Sep 27; 354:i5055. Bien J, Prasad V. PMID: 27677772.
      View in: PubMed   Mentions: 3     Fields:    
    287. Perspective: The precision-oncology illusion. Nature. 2016 09 08; 537(7619):S63. Prasad V. PMID: 27602743.
      View in: PubMed   Mentions: 114     Fields:    Translation:Humans
    288. Negative trials in ovarian cancer: is there such a thing as too much optimism? Ecancermedicalscience. 2016; 10:ed58. Gyawali B, Prasad V. PMID: 27594913; PMCID: PMC4990052.
      View in: PubMed   Mentions: 2  
    289. Precision medicine in acute myeloid leukemia: Hope, hype or both? Leuk Res. 2016 09; 48:73-7. Prasad V, Gale RP. PMID: 27497757.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    290. Implications of Proposed Medicare Reforms to Counteract High Cancer Drug Prices. JAMA. 2016 Jul 19; 316(3):271-2. Mailankody S, Prasad V. PMID: 27149663.
      View in: PubMed   Mentions: 7     Fields:    
    291. Thinking Systematically About the Off-Label Use of Cancer Drugs and Combinations for Patients Who Have Exhausted Proven Therapies. Oncologist. 2016 09; 21(9):1031-2. Mailankody S, Prasad V. PMID: 27401893; PMCID: PMC5016075.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    292. Wearables, Smartphones and Novel Anticoagulants: We Will Treat More Atrial Fibrillation, but Will Patients Be Better Off? J Gen Intern Med. 2016 11; 31(11):1367-1368. Cifu A, Prasad V. PMID: 27338593; PMCID: PMC5071280.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    293. Blood-Based Screening for Colon Cancer: A Disruptive Innovation or Simply a Disruption? JAMA. 2016 Jun 21; 315(23):2519-20. Parikh RB, Prasad V. PMID: 27305625.
      View in: PubMed   Mentions: 14     Fields:    Translation:HumansCells
    294. The UK Cancer Drugs Fund Experiment and the US Cancer Drug Cost Problem: Bearing the Cost of Cancer Drugs Until It Is Unbearable. Mayo Clin Proc. 2016 06; 91(6):707-12. Prasad V, Mailankody S. PMID: 27261866.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    295. ASCO Plenary Sessions: impact, legacy, future. Semin Oncol. 2016 06; 43(3):321-6. Vandross A, Prasad V, Mailankody S. PMID: 27178681.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    296. Is prostate cancer screening responsible for the negative results of prostate cancer treatment trials? Med Hypotheses. 2016 Aug; 93:71-3. Prasad V. PMID: 27372859.
      View in: PubMed   Mentions:    Fields:    Translation:HumansPHPublic Health
    297. Strength of Validation for Surrogate End Points Used in the US Food and Drug Administration's Approval of Oncology Drugs. Mayo Clin Proc. 2016 May 10. Kim C, Prasad V. PMID: 27236424; PMCID: PMC5104665.
      View in: PubMed   Mentions: 27     Fields:    
    298. Spontaneous Cystic Penile Vascular Malformation in an Adolescent and Review of the Literature. Urology. 2016 Nov; 97:197-199. Preece J, Prasad V, Schober M, DaJusta DG. PMID: 27112512.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    299. Balancing Accelerated Approval for Drugs With Accelerated Withdrawal--Reply. JAMA Intern Med. 2016 Apr; 176(4):567. Kim C, Prasad V. PMID: 27043117.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    300. Characteristics and Conflicts of Public Speakers at Meetings of the Oncologic Drugs Advisory Committee to the US Food and Drug Administration. JAMA Intern Med. 2016 Mar; 176(3):389-91. Abola MV, Prasad V. PMID: 26831527.
      View in: PubMed   Mentions: 11     Fields:    Translation:Humans
    301. How Should Research Be Funded? Difficulties With the Argument for Proportionality to Causes of Death or Years of Life Lost. J Natl Compr Canc Netw. 2016 Mar; 14(3):365-6. Prasad V. PMID: 26957620.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    302. Assessing the Eventual Publication of Clinical Trial Abstracts Submitted to a Large Annual Oncology Meeting. Oncologist. 2016 Mar; 21(3):261-8. Massey PR, Wang R, Prasad V, Bates SE, Fojo T. PMID: 26888691; PMCID: PMC4786361.
      View in: PubMed   Mentions: 15     Fields:    Translation:Humans
    303. Precision oncology: origins, optimism, and potential. Lancet Oncol. 2016 Feb; 17(2):e81-e86. Prasad V, Fojo T, Brada M. PMID: 26868357.
      View in: PubMed   Mentions: 79     Fields:    Translation:HumansCells
    304. Vinay Prasad on the use of exaggerated language in cancer research, and how it can mislead doctors, patients, and the public. Oncology (Williston Park). 2016 Feb; 30(2):120-1. Prasad VK. PMID: 26888789.
      View in: PubMed   Mentions:    Fields:    Translation:HumansAnimals
    305. Application of Medicare's New Technology Add-on Payment Program for Blinatumomab. JAMA Oncol. 2016 Feb; 2(2):165-6. Dhruva SS, Prasad V. PMID: 26720844.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    306. Reply to Dr. Leon: true but unrelated. J Clin Epidemiol. 2016 07; 75:127. Prasad V. PMID: 26808818.
      View in: PubMed   Mentions:    Fields:    
    307. Why cancer screening has never been shown to "save lives"--and what we can do about it. BMJ. 2016 Jan 06; 352:h6080. Prasad V, Lenzer J, Newman DH. PMID: 26740343.
      View in: PubMed   Mentions: 40     Fields:    Translation:Humans
    308. In Reply--Is There a Need for "Bias Police" in Industry-Sponsored Research? Mayo Clin Proc. 2016 Jan; 91(1):121. Prasad V, Berger VW. PMID: 26763516.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    309. The Use of Superlatives in Cancer Research. JAMA Oncol. 2016 Jan; 2(1):139-41. Abola MV, Prasad V. PMID: 26512913.
      View in: PubMed   Mentions: 14     Fields:    Translation:Humans
    310. Ethics of Clinical Trials in Low-Resource Settings: Lessons From Recent Trials in Cancer Medicine. J Glob Oncol. 2016 Feb; 2(1):1-3. Prasad V, Kumar H, Mailankody S. PMID: 28717675; PMCID: PMC5497740.
      View in: PubMed   Mentions: 4     Fields:    
    311. Cardiovascular risk assessment in oncological clinical trials: is there a role for centralized events adjudication? Eur J Heart Fail. 2016 Feb; 18(2):128-32. Vaduganathan M, Prasad V. PMID: 26663426.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    312. Translation failure and medical reversal: Two sides to the same coin. Eur J Cancer. 2016 Jan; 52:197-200. Prasad V. PMID: 26689866.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansAnimals
    313. Cancer Drugs Approved on the Basis of a Surrogate End Point and Subsequent Overall Survival: An Analysis of 5 Years of US Food and Drug Administration Approvals. JAMA Intern Med. 2015 Dec; 175(12):1992-4. Kim C, Prasad V. PMID: 26502403.
      View in: PubMed   Mentions: 98     Fields:    Translation:Humans
    314. Medical Debates and Medical Reversal. J Gen Intern Med. 2015 Dec; 30(12):1729-30. Cifu AS, Prasad VK. PMID: 26224155; PMCID: PMC4636561.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    315. Meta-Analyses of Statin Therapy for Primary Prevention Do Not Answer Key Questions: An Empirical Appraisal of 5 Years of Statin Meta-Analyses. Am J Cardiovasc Drugs. 2015 Dec; 15(6):379-86. Huded C, Prasad V. PMID: 26141958.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansPHPublic Health
    316. The use of gene expression profiling and mutation analysis increases the cost of care for patients with carcinoma of unknown primary; does it also improve survival? Eur J Cancer. 2016 Feb; 54:159-162. Prasad V, Oseran A, Fakhrejahani F. PMID: 26608119.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    317. Characteristics of Exceptional or Super Responders to Cancer Drugs. Mayo Clin Proc. 2015 Dec; 90(12):1639-49. Prasad V, Vandross A. PMID: 26546106.
      View in: PubMed   Mentions: 14     Fields:    Translation:Humans
    318. Prostate Cancer Screening: The Pendulum has Swung, and the Burden of Proof Is with Proponents. Am Fam Physician. 2015 10 15; 92(8):678-80. Prasad V. PMID: 26554407.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansPHPublic Health
    319. Susan Bates, M.D., and Antonio "Tito" Fojo, M.D., Ph.D.: Thirty Years of Research, Discovery, Service, and Mentorship at the National Cancer Institute. Oncologist. 2015 Nov; 20(11):1344-6. Mailankody S, Prasad V. PMID: 26449381; PMCID: PMC4718435.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    320. Pricing and Value of Cancer Drugs--Reply. JAMA Oncol. 2015 Sep; 1(6):842-3. Mailankody S, Prasad V. PMID: 26355867.
      View in: PubMed   Mentions:    Fields:    Translation:HumansPHPublic Health
    321. Colorectal Cancer Survival Gains and Novel Treatment Regimens: A Systematic Review and Analysis. JAMA Oncol. 2015 Sep; 1(6):787-95. Jawed I, Wilkerson J, Prasad V, Duffy AG, Fojo T. PMID: 26181239.
      View in: PubMed   Mentions: 27     Fields:    Translation:Humans
    322. How should we assess the value of innovative drugs in oncology? Lessons from cost-effectiveness analyses. Blood. 2015 Oct 08; 126(15):1860-1. Prasad V, Mailankody S. PMID: 26320099; PMCID: PMC4600021.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    323. Clinical trial spots for cancer patients by tumour type: The cancer trials portfolio at clinicaltrials.gov. Eur J Cancer. 2015 Nov; 51(17):2718-23. Prasad V, Goldstein JA. PMID: 26321010; PMCID: PMC4663106.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    324. Non-invasive, serum DNA pregnancy testing leading to incidental discovery of cancer: a good thing? Eur J Cancer. 2015 Nov; 51(16):2272-4. Prasad V. PMID: 26278647.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    325. Hard-Wired Bias: How Even Double-Blind, Randomized Controlled Trials Can Be Skewed From the Start. Mayo Clin Proc. 2015 Sep; 90(9):1171-5. Prasad V, Berger VW. PMID: 26277702; PMCID: PMC4567484.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    326. The role of censoring on progression free survival: oncologist discretion advised. Eur J Cancer. 2015 Nov; 51(16):2269-71. Prasad V, Bilal U. PMID: 26259493.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    327. The Strength of Association Between Surrogate End Points and Survival in Oncology: A Systematic Review of Trial-Level Meta-analyses. JAMA Intern Med. 2015 Aug; 175(8):1389-98. Prasad V, Kim C, Burotto M, Vandross A. PMID: 26098871.
      View in: PubMed   Mentions: 82     Fields:    Translation:Humans
    328. Authorship Inflation in Medical Publications. Inquiry. 2015; 52. Tilak G, Prasad V, Jena AB. PMID: 26228035; PMCID: PMC4943864.
      View in: PubMed   Mentions: 19     Fields:    
    329. Mutations in COQ4, an essential component of coenzyme Q biosynthesis, cause lethal neonatal mitochondrial encephalomyopathy. J Med Genet. 2015 Sep; 52(9):627-35. Chung WK, Martin K, Jalas C, Braddock SR, Juusola J, Monaghan KG, Warner B, Franks S, Yudkoff M, Lulis L, Rhodes RH, Prasad V, Torti E, Cho MT, Shinawi M. PMID: 26185144.
      View in: PubMed   Mentions: 17     Fields:    Translation:Humans
    330. Optimization of CO₂ fixation by Chlorella kessleri cultivated in a closed raceway photo-bioreactor. Bioresour Technol. 2015 Oct; 194:144-55. Kasiri S, Ulrich A, Prasad V. PMID: 26188557.
      View in: PubMed   Mentions:    Fields:    Translation:Animals
    331. Five Years of Cancer Drug Approvals: Innovation, Efficacy, and Costs. JAMA Oncol. 2015 Jul; 1(4):539-40. Mailankody S, Prasad V. PMID: 26181265.
      View in: PubMed   Mentions: 86     Fields:    Translation:HumansPHPublic Health
    332. Response. Chest. 2015 Jul; 148(1):e31-e32. Rho J, Ho N, Prasad V. PMID: 26149564; PMCID: PMC5831562.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    333. Distinctive clinical characteristics of malignant mesothelioma in young patients. Oncotarget. 2015 Jun 30; 6(18):16766-73. Thomas A, Chen Y, Yu T, Gill A, Prasad V. PMID: 26202904; PMCID: PMC4599306.
      View in: PubMed   Mentions: 12     Fields:    Translation:Humans
    334. Multiplying therapies and reducing toxicity in metastatic melanoma. Cancer Biol Ther. 2015; 16(7):1014-8. Massey PR, Prasad V, Figg WD, Fojo T. PMID: 26016850; PMCID: PMC4623483.
      View in: PubMed   Mentions: 4     Fields:    
    335. Do we need randomised trials for rare cancers? Eur J Cancer. 2015 Jul; 51(11):1355-7. Prasad V, Oseran A. PMID: 25963018.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    336. Emphasizing unique strengths and eliminating redundancy for research in low-income and middle-income countries: Lessons from a South American country. Cancer. 2015 Aug 15; 121(16):2668-70. Burotto M, Prasad V. PMID: 25903222.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    337. Non-inferiority trials: why oncologists must remain wary. Lancet Oncol. 2015 Apr; 16(4):364-6. Burotto M, Prasad V, Fojo T. PMID: 25846084.
      View in: PubMed   Mentions: 11     Fields:    Translation:Humans
    338. In situ biodegradation of naphthenic acids in oil sands tailings pond water using indigenous algae-bacteria consortium. Bioresour Technol. 2015; 187:97-105. Mahdavi H, Prasad V, Liu Y, Ulrich AC. PMID: 25841188.
      View in: PubMed   Mentions: 7     Fields:    Translation:CellsPHPublic Health
    339. Primary chemoprevention of breast cancer: Are the adverse effects too burdensome? CMAJ. 2015 Jun 16; 187(9):E276-E278. Prasad V, Diener-West M. PMID: 25802306; PMCID: PMC4467955.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    340. Disease specific productivity of american cancer hospitals. PLoS One. 2015; 10(3):e0121233. Goldstein JA, Prasad V. PMID: 25781329; PMCID: PMC4364111.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    341. But how many people died? Health outcomes in perspective. Cleve Clin J Med. 2015 Mar; 82(3):146-50. Prasad V. PMID: 25932737.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    342. Mortality and treatment patterns among patients hospitalized with acute cardiovascular conditions during dates of national cardiology meetings. JAMA Intern Med. 2015 Feb; 175(2):237-44. Jena AB, Prasad V, Goldman DP, Romley J. PMID: 25531231; PMCID: PMC4314435.
      View in: PubMed   Mentions: 21     Fields:    Translation:Humans
    343. Modern drug development: which patients should come first? JAMA. 2014 Dec 24-31; 312(24):2619-20. Vaduganathan M, Prasad V. PMID: 25420013.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    344. The withdrawal of drugs for commercial reasons: the incomplete story of tositumomab. JAMA Intern Med. 2014 Dec; 174(12):1887-8. Prasad V. PMID: 25383420.
      View in: PubMed   Mentions: 13     Fields:    Translation:Humans
    345. The College of American Pathologists guidelines for whole slide imaging validation are feasible for pediatric pathology: a pediatric pathology practice experience. Pediatr Dev Pathol. 2015 Mar-Apr; 18(2):109-16. Arnold MA, Chenever E, Baker PB, Boué DR, Fung B, Hammond S, Hendrickson BW, Kahwash SB, Pierson CR, Prasad V, Nicol KK, Barr T. PMID: 25387255.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    346. It is time to stop screening for prostate cancer. JAMA Intern Med. 2014 Nov; 174(11):1841-2. Prasad V. PMID: 25178980.
      View in: PubMed   Mentions:    Fields:    Translation:HumansPHPublic Health
    347. Primary care physicians' role in counseling about gun safety. Am Fam Physician. 2014 Nov 01; 90(9):619-20. Jena AB, Prasad V. PMID: 25368919.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    348. Exemestane with ovarian suppression in premenopausal breast cancer. N Engl J Med. 2014 10 02; 371(14):1358. Prasad V. PMID: 25271613.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    349. US News and World Report cancer hospital rankings: do they reflect measures of research productivity? PLoS One. 2014; 9(9):e107803. Prasad V, Goldstein JA. PMID: 25247921; PMCID: PMC4172593.
      View in: PubMed   Mentions: 13     Fields:    Translation:Humans
    350. Rosiglitazone, medical reversal, and back to basics for diabetes. Am Fam Physician. 2014 Sep 15; 90(6):368, 370. Prasad V. PMID: 25251229.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    351. The Peltzman effect and compensatory markers in medicine. Healthc (Amst). 2014 Sep 01; 2(3):170-172. Prasad V, Jena AB. PMID: 25396116; PMCID: PMC4226525.
      View in: PubMed   Mentions: 3     Fields:    
    352. Long-term effects of the 2003 ACGME resident duty hour reform on hospital mortality. Mayo Clin Proc. 2014 Jul; 89(7):1023-5. Jena AB, Prasad V, Romley JA. PMID: 24996240; PMCID: PMC4275102.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    353. Statins, primary prevention, and overall mortality. Ann Intern Med. 2014 Jun 17; 160(12):867-9. Prasad V. PMID: 24935491.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansPHPublic Health
    354. The declining demand for hospital care as a rationale for duty hour reform. J Gen Intern Med. 2014 Oct; 29(10):1400-3. Jena AB, DePasse JW, Prasad V. PMID: 24866469; PMCID: PMC4175648.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    355. Balloon brachytherapy for breast cancer prove that it works? Or, prove that it doesn't? J Cancer Res Clin Oncol. 2014 Aug; 140(8):1353-7. Prasad V. PMID: 24858568.
      View in: PubMed   Mentions:    Fields:    Translation:HumansPHPublic Health
    356. Rebuttal from Dr Rho et al. Chest. 2014 May; 145(5):943-4. Rho J, Ho N, Prasad V. PMID: 24798833; PMCID: PMC4011656.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    357. Counterpoint: were industry-sponsored roflumilast trials appropriate? No. Chest. 2014 May; 145(5):939-42. Rho J, Ho N, Prasad V. PMID: 24798831; PMCID: PMC4011655.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    358. The reply. Am J Med. 2014 May; 127(5):e15. Prasad V, Shea N. PMID: 24758876.
      View in: PubMed   Mentions:    Fields:    
    359. Comparative effectiveness questions in oncology. N Engl J Med. 2014 Apr 17; 370(16):1478-81. Mailankody S, Prasad V. PMID: 24738667.
      View in: PubMed   Mentions: 17     Fields:    Translation:Humans
    360. Oral anticancer drugs: how limited dosing options and dose reductions may affect outcomes in comparative trials and efficacy in patients. J Clin Oncol. 2014 May 20; 32(15):1620-9. Prasad V, Massey PR, Fojo T. PMID: 24711558; PMCID: PMC4026582.
      View in: PubMed   Mentions: 21     Fields:    Translation:Humans
    361. Why do we continue to adopt medical practices based on pathophysiology alone when we should be insisting on clinical trials? J Clin Epidemiol. 2014 Apr; 67(4):361-3. Prasad V, Ho N. PMID: 24581292.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    362. Can a resident's publication record predict fellowship publications? PLoS One. 2014; 9(3):e90140. Prasad V, Rho J, Selvaraj S, Cheung M, Vandross A, Ho N. PMID: 24658088; PMCID: PMC3962333.
      View in: PubMed   Mentions:    Fields:    
    363. Synovial chondromatosis of the cervical spine: a case report and review of the literature. Pediatr Dev Pathol. 2014 May-Jun; 17(3):221-5. Shaw A, Zibly Z, Prasad V, Ikeda D, Boue D, Governale LS. PMID: 24650324.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    364. Shameful. CMAJ. 2014 Apr 01; 186(6):472. Prasad V. PMID: 24638022; PMCID: PMC3971042.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    365. Use of the Word "Cure" in the Oncology Literature. Am J Hosp Palliat Care. 2015 Aug; 32(5):477-83. Prasad V. PMID: 24558172.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    366. Aditya Jyot-Diabetic Retinopathy in Urban Mumbai Slums Study (AJ-DRUMSS): study design and methodology - report 1. Ophthalmic Epidemiol. 2014 Feb; 21(1):51-60. Sunita M, Desai S, Vinay P, Moolani S, Rai N, Deepen S, Ashwini R, Manish S, Hemangi G, Abdal O, Kulkarni P, Chakravarti A, Uthra S, Raman R, Radhika S, Natarajan S, Kumaramanickavel G, McCarty C. PMID: 24467563.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    367. Fatal extraintestinal adrenal malignancy in a 12-year-old girl with familial adenomatous polyposis. J Pediatr Gastroenterol Nutr. 2014 Feb; 58(2):e19-20. Rauch LB, Erdman SH, Aldrink JH, Ranalli MA, Prasad V, Hoffman RP. PMID: 23575299.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    368. Failing to improve overall survival because post-protocol survival is long: fact, myth, excuse or improper study design? J Cancer Res Clin Oncol. 2014 Apr; 140(4):521-4. Prasad V, Vandross A. PMID: 24474554.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    369. Does the declining lethality of gunshot injuries mask a rising epidemic of gun violence in the United States? J Gen Intern Med. 2014 Jul; 29(7):1065-9. Jena AB, Sun EC, Prasad V. PMID: 24452421; PMCID: PMC4061370.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    370. Media coverage of medical journals: do the best articles make the news? PLoS One. 2014; 9(1):e85355. Selvaraj S, Borkar DS, Prasad V. PMID: 24465543; PMCID: PMC3894978.
      View in: PubMed   Mentions: 13     Fields:    Translation:Humans
    371. Evidence-based de-implementation for contradicted, unproven, and aspiring healthcare practices. Implement Sci. 2014 Jan 08; 9:1. Prasad V, Ioannidis JP. PMID: 24398253; PMCID: PMC3892018.
      View in: PubMed   Mentions: 112     Fields:    
    372. Regarding empiricism and rationalism in medicine and 2 medical worldviews. Mayo Clin Proc. 2014 Jan; 89(1):137. Prasad V. PMID: 24388033.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    373. Eliminating chronic kidney disease… as a diagnosis. Pol Arch Med Wewn. 2014; 124(1-2):7-9. Prasad V, Cifu A. PMID: 24531346.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    374. Comment on "Eliminating chronic kidney disease... as a diagnosis". Authors' reply. Pol Arch Med Wewn. 2014; 124(4):214. Prasad V, Cifu A. PMID: 24732318.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    375. The accelerated approval of oncologic drugs: lessons from ponatinib. JAMA. 2014 Jan 22-29; 311(4):353-4. Prasad V, Mailankody S. PMID: 24449310.
      View in: PubMed   Mentions: 16     Fields:    Translation:HumansPHPublic Health
    376. Further thoughts on why there are good data supporting the inferior vena cava filter. JAMA Intern Med. 2014 Jan; 174(1):164-5. Prasad V, Rho J, Cifu A. PMID: 24394930.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    377. The misguided ethics of crossover trials. Contemp Clin Trials. 2014 Mar; 37(2):167-9. Prasad V, Grady C. PMID: 24365533; PMCID: PMC3981898.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    378. The reversal of cardiology practices: interventions that were tried in vain. Cardiovasc Diagn Ther. 2013 Dec; 3(4):228-35. Prasad V, Cifu A. PMID: 24400206; PMCID: PMC3878120.
      View in: PubMed   Mentions:
    379. The reply. Am J Med. 2013 Dec; 126(12):e45. Shea N, Prasad V. PMID: 24262747.
      View in: PubMed   Mentions:    Fields:    
    380. Dense breasts and legislating medicine. Cleve Clin J Med. 2013 Dec; 80(12):768-70. Ho N, Kim J, Prasad V. PMID: 24307160.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    381. The reply. Am J Med. 2014 Mar; 127(3):e21. Prasad V, Kim J, Rho J. PMID: 24291600.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    382. Firearm legislation and gun-related fatalities. JAMA Intern Med. 2013 Nov 25; 173(21):2011. Jena AB, Sun EC, Prasad V. PMID: 24276051.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    383. Persistent reservations against the premedical and medical curriculum. Perspect Med Educ. 2013 Nov; 2(5-6):335-9. Prasad V. PMID: 23670684; PMCID: PMC3824759.
      View in: PubMed   Mentions: 1     Fields:    
    384. Observational studies cannot justify the inferior vena cava filter. Am J Med. 2014 Mar; 127(3):e15. Prasad V. PMID: 24560327.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    385. The inferior vena cava filter--reply. JAMA Intern Med. 2013 Oct 14; 173(18):1754-5. Prasad V, Rho J, Cifu A. PMID: 24126777.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    386. Powering cancer screening for overall mortality. Ecancermedicalscience. 2013; 7:ed27. Prasad V. PMID: 24883096; PMCID: PMC4025495.
      View in: PubMed   Mentions:
    387. The overdiagnosis of pneumonia. Cleve Clin J Med. 2013 Oct; 80(10):616-8. Prasad V. PMID: 24085804.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    388. In reply I-reversal of medical practices. Mayo Clin Proc. 2013 Oct; 88(10):1183-4. Prasad V, Cifu A. PMID: 24079692.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    389. Why randomized controlled trials are needed to accept new practices: 2 medical worldviews. Mayo Clin Proc. 2013 Oct; 88(10):1046-50. Prasad V. PMID: 24079676.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    390. Utility of tissue transglutaminase immunohistochemistry in pediatric duodenal biopsies: patterns of expression and role in celiac disease-a clinicopathologic review. Patholog Res Int. 2013; 2013:602985. Almarzooqi S, Houston RH, Prasad V. PMID: 24195009; PMCID: PMC3782127.
      View in: PubMed   Mentions:
    391. Xanthogranulomatous appendicitis in a child: report of a case and review of the literature. Case Rep Med. 2013; 2013:498191. Al-Rawabdeh SM, Prasad V, King DR, Kahwash SB. PMID: 24093025; PMCID: PMC3777195.
      View in: PubMed   Mentions: 9  
    392. Why resident physicians stay late. CMAJ. 2013 Sep 17; 185(13):1184. Prasad V. PMID: 24003103; PMCID: PMC3778495.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    393. Duty hour reform in a shifting medical landscape. J Gen Intern Med. 2013 Sep; 28(9):1238-40. Jena AB, Prasad V. PMID: 23568191; PMCID: PMC3744286.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    394. Osmotic virial coefficients of hydroxyethyl starch from aqueous hydroxyethyl starch-sodium chloride vapor pressure osmometry. J Phys Chem B. 2013 Sep 05; 117(35):10231-40. Cheng J, Gier M, Ross-Rodriguez LU, Prasad V, Elliott JA, Sputtek A. PMID: 23862979.
      View in: PubMed   Mentions:    Fields:    
    395. Handheld ultrasounds: pocket sized, but pocket ready? Am J Med. 2013 Oct; 126(10):845-6. Kim JK, Rho J, Prasad V. PMID: 23910521.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    396. Taking care of sick patients. CMAJ. 2013 Aug 06; 185(11):1008. Prasad V. PMID: 23877668; PMCID: PMC3735754.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    397. Evaluating health system processes with randomized controlled trials. JAMA Intern Med. 2013 Jul 22; 173(14):1279-80. Ioannidis JP, Prasad V. PMID: 23689271.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    398. A decade of reversal: an analysis of 146 contradicted medical practices. Mayo Clin Proc. 2013 Aug; 88(8):790-8. Prasad V, Vandross A, Toomey C, Cheung M, Rho J, Quinn S, Chacko SJ, Borkar D, Gall V, Selvaraj S, Ho N, Cifu A. PMID: 23871230.
      View in: PubMed   Mentions: 97     Fields:    Translation:Humans
    399. Treatment of moderate to severe hidradenitis suppurativa. Ann Intern Med. 2013 Jul 02; 159(1):72. Prasad V. PMID: 23817709.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    400. Open issues with open access publication. Am J Med. 2013 Jul; 126(7):563-4. Shea N, Prasad V. PMID: 23787194.
      View in: PubMed   Mentions: 4     Fields:    
    401. Routine noninvasive testing and highly sensitive troponin immunoassays--reply. JAMA Intern Med. 2013 May 13; 173(9):833-4. Prasad V, Cheung M, Cifu A. PMID: 23700018.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    402. Subclavian vein aneurysm secondary to a benign vessel wall hamartoma. Pediatr Radiol. 2013 Nov; 43(11):1528-31. Warren P, Spaeth M, Prasad V, McConnell P. PMID: 23636539.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    403. Falsification end points for observational studies--reply. JAMA. 2013 May 01; 309(17):1770-1. Jena AB, Prasad V. PMID: 23632713.
      View in: PubMed   Mentions: 1     Fields:    
    404. Double-crossed: why crossover in clinical trials may be distorting medical science. J Natl Compr Canc Netw. 2013 May 01; 11(5):625-7. Prasad V. PMID: 23667211.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    405. The inferior vena cava filter: how could a medical device be so well accepted without any evidence of efficacy? JAMA Intern Med. 2013 Apr 08; 173(7):493-5; discussion 495. Prasad V, Rho J, Cifu A. PMID: 23552611.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansPHPublic Health
    406. Characteristics of cluster randomized trials: are they living up to the randomized trial? JAMA Intern Med. 2013 Feb 25; 173(4):313-5. Selvaraj S, Prasad V. PMID: 23337957.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    407. Observational studies often make clinical practice recommendations: an empirical evaluation of authors' attitudes. J Clin Epidemiol. 2013 Apr; 66(4):361-366.e4. Prasad V, Jorgenson J, Ioannidis JP, Cifu A. PMID: 23384591.
      View in: PubMed   Mentions: 15     Fields:    Translation:Humans
    408. Prespecified falsification end points: can they validate true observational associations? JAMA. 2013 Jan 16; 309(3):241-2. Prasad V, Jena AB. PMID: 23321761.
      View in: PubMed   Mentions: 91     Fields:    
    409. Probiotics, prebiotics, synbiotics and naturally fermented foods: why more may be more. Ann Gastroenterol. 2013; 26(3):277-278. Ho N, Prasad V. PMID: 24714309; PMCID: PMC3959447.
      View in: PubMed   Mentions: 1  
    410. When research evidence is misleading. Virtual Mentor. 2013 Jan 01; 15(1):29-33. Huded C, Rosno J, Prasad V. PMID: 23356804.
      View in: PubMed   Mentions:    Fields:    
    411. Couple therapy for posttraumatic stress disorder. JAMA. 2012 Dec 19; 308(23):2458; author reply 2458. Prasad V. PMID: 23288147.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    412. Holiday reading: The facts are the facts. CMAJ. 2012 Dec 11; 184(18):2029-30. Prasad V. PMID: 23230055; PMCID: PMC3519195.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    413. Freedom to innovate: the perils of centralized medical research-reply. Arch Intern Med. 2012 Nov 26; 172(21):1692-3. Prasad V, Rho J, Cifu A. PMID: 23753119.
      View in: PubMed   Mentions:    Fields:    
    414. Chest pain in the emergency department: the case against our current practice of routine noninvasive testing. Arch Intern Med. 2012 Oct 22; 172(19):1506-9. Prasad V, Cheung M, Cifu A. PMID: 22987111.
      View in: PubMed   Mentions: 14     Fields:    Translation:Humans
    415. An unmeasured harm of screening. Arch Intern Med. 2012 Oct 22; 172(19):1442-3. Prasad V. PMID: 22987011.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    416. Raise the bar even higher for primary prevention interventions-reply. Arch Intern Med. 2012 Sep 24; 172(17):1352-3. Prasad V, Vandross A. PMID: 23752665.
      View in: PubMed   Mentions:    Fields:    
    417. The conundrum of cost-effectiveness. Cleve Clin J Med. 2012 Sep; 79(9):610-1. Prasad V. PMID: 22949341.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    418. Publication trends among internal medicine residents and graduates. Am J Med. 2012 Sep; 125(9):939-44. Prasad V, Rho J, Selvaraj S, Toomey C, Vandross A, Ho N. PMID: 22938929.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    419. The diagnosis and treatment of pulmonary embolism: a metaphor for medicine in the evidence-based medicine era. Arch Intern Med. 2012 Jun 25; 172(12):955-8. Prasad V, Rho J, Cifu A. PMID: 22473672.
      View in: PubMed   Mentions: 12     Fields:    Translation:Humans
    420. The apples and oranges of cost-effectiveness. Cleve Clin J Med. 2012 Jun; 79(6):377-9. Prasad V. PMID: 22660868.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    421. Cardiovascular primary prevention: how high should we set the bar? Arch Intern Med. 2012 Apr 23; 172(8):656-9; discussion 659. Prasad V, Vandross A. PMID: 22529231.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansPHPublic Health
    422. New frontiers for stroke prevention in atrial fibrillation. Cerebrovasc Dis. 2012; 33(3):199-208. Prasad V, Kaplan RM, Passman RS. PMID: 22261539.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    423. Reversals of established medical practices: evidence to abandon ship. JAMA. 2012 Jan 04; 307(1):37-8. Prasad V, Cifu A, Ioannidis JP. PMID: 22215160.
      View in: PubMed   Mentions: 44     Fields:    Translation:HumansPHPublic Health
    424. Medical reversal: why we must raise the bar before adopting new technologies. Yale J Biol Med. 2011 Dec; 84(4):471-8. Prasad V, Cifu A. PMID: 22180684; PMCID: PMC3238324.
      View in: PubMed   Mentions: 20     Fields:    Translation:Humans
    425. Selective therapeutic hypothermia: a review of invasive and noninvasive techniques. Arq Neuropsiquiatr. 2011 Dec; 69(6):981-7. Straus D, Prasad V, Munoz L. PMID: 22297891.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    426. The cardiovascular biomarker conundrum: challenges and solutions. JAMA. 2011 Nov 16; 306(19):2151-2. Prasad V, Bonow RO. PMID: 22089725.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    427. Are we treating professionalism professionally? Medical school behavior as predictors of future outcomes. Teach Learn Med. 2011 Oct; 23(4):337-41. Prasad V. PMID: 22004318.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    428. Clostridium difficile diarrhea and fecal transplantation. J Clin Gastroenterol. 2011 Sep; 45(8):742-3. Ho N, Prasad V. PMID: 21555950.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCells
    429. The frequency of medical reversal. Arch Intern Med. 2011 Oct 10; 171(18):1675-6. Prasad V, Gall V, Cifu A. PMID: 21747003.
      View in: PubMed   Mentions: 27     Fields:    Translation:Humans
    430. Effect of clinical vignettes on senior medical students' opinions of climate change. South Med J. 2011 Jun; 104(6):401-4. Prasad V, Thistlethwaite W, Dale W. PMID: 21886028.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    431. Lacking the incentive to cure? Recurring Clostridium difficile diarrhea and our reluctance to use fecal transplantation. J Clin Gastroenterol. 2011 Apr; 45(4):379-80. Ho N, Prasad V. PMID: 21278582.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCellsPHPublic Health
    432. Steroids in infection: an old wives' tale. CMAJ. 2011 Jan 11; 183(1):83; author reply 83-4. Prasad V. PMID: 21220464; PMCID: PMC3017262.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    433. Caution needed when predicting problem residents. Acad Med. 2011 Jan; 86(1):2; author reply 2. Prasad V. PMID: 21191193.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    434. Holiday reading: A la carte medicine. CMAJ. 2010 Dec 14; 182(18):2011-2. Prasad V. PMID: 21149538; PMCID: PMC3001514.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    435. Baseline event rate, the Concorde fallacy, and the topography of cardiac risk. Med Hypotheses. 2010 Dec; 75(6):639-41. Prasad V. PMID: 20800366.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    436. Language in the end. Explaining the death of a loved one. J Gen Intern Med. 2010 Aug; 25(8):884-5. Prasad V. PMID: 20443071; PMCID: PMC2896594.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    437. Reclaiming the morbidity and mortality conference: between Codman and Kundera. Med Humanit. 2010 Dec; 36(2):108-11. Prasad V. PMID: 21393293.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    438. Perspective: beyond storytelling in medicine: an encounter-based curriculum. Acad Med. 2010 May; 85(5):794-8. Prasad V. PMID: 20520028.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    439. Toward a meaningful alternative medicine. Hastings Cent Rep. 2009 Sep-Oct; 39(5):16-8. Prasad V. PMID: 19806774.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    Vinayak's Networks
    Concepts (822)
    Derived automatically from this person's publications.
    _
    Co-Authors (12)
    People in Profiles who have published with this person.
    _
    Similar People (60)
    People who share similar concepts with this person.
    _
    Same Department
    Search Department
    _